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ABSTRACT 
 
 The Tyrosine kinase receptor AXL belongs to the TAM (Tyro3, AXL 
and Mer) family, whose members are characterized by a highly conserved 
kinase domain and adhesion molecule-like domains in the extracellular region.  
There are several reports showing AXL overexpression in cancer and its 
transforming potential, depicting its ability to drive tumor formation, 
progression and resistance to different anti-cancer agents; hence, AXL receptor 
is a clinically validated cancer target.  Heat shock protein 90 (HSP90) is a 
critical player in regulating the maturation, stability, and activity of its client 
proteins.  HSP90 inhibition causes depletion of multiple oncogenic client 
proteins, leading to blockade of many key cancer causing pathways.  HSP90 
inhibitors that derived from geldanamycin, such as 17-AAG, have emerged as 
promising therapeutic agents for cancer treatment and few of them have 
entered clinical trials. 
 In this study we show that AXL is a novel client of HSP90, as the two 
structurally unrelated HSP90 inhibitors Radicicol or 17-AAG, induced a time- 
and dose-dependent downregulation of endogenous or ectopically expressed 
AXL protein. Using biotin and 35S-methionine labelling of the 
biogenesis/trafficking receptor upon 17-AAG treatment we showed that 17-
AAG induced depletion of AXL on the plasma membrane, by mediating 
degradation of fully glycosylated AXL receptor from internal organelles and 
therefore restricting its transport to the cell surface.  We demonstrated that 17-
AAG induced AXL polyubiquitination and subsequent degradation via 
proteasome.  HSP90 functions in the context of a multi-protein chaperone 
complex.  By co-immunoprecipitation experiments, interactions between AXL 
and the components of chaperone complex like HSP90 itself, HSP70, and 
Ubiquitin E3 ligase CHIP (Carboxy terminus of Hsc70 Interacting Protein) 
were shown to be modulated by 17-AAG treatment.  By contrast to wt CHIP, 
the functionally inactive CHIP mutant, CHIP K30A failed to accumulate AXL 
polyubiquitinated species even in the presence of 17-AAG, suggesting the 
involvement of endogenous CHIP in 17-AAG induced AXL 
polyubiquitination.  We could also show that, it is the intracellular domain 
(ICD) of AXL containing the TK domain that is crucial to acquire 17-AAG 
sensitivity, as the AXL ICD-deleted mutant is insensitive to 17-AAG mediated 
degradation.  However, AXL kinase activity is not required for 17-AAG 
mediated AXL loss, since inhibition of kinase activity by Bosutinib did not 
affect AXL sensitivity to 17-AAG.  Similarly, AXL kinase dead mutant was as 
sensitive as the wt receptor to 17-AAG induced degradation.  Finally, we also 
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demonstrated that 17-AAG induced AXL downregulation could interfere with 
AXL mediated biological activity, measured as activation of transcription from 
the AP1 promoter, suggesting a possible therapeutic approach to counteract 
AXL driven oncogenic activity or drug resistance.  Our data convincingly 
clarify the molecular basis of AXL downregulation by HSP90 inhibitor 17-
AAG and suggest that HSP90 inhibition in anti-cancer therapy can exert its 
effect through inhibition of multiple kinases, including AXL itself. 
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1. BACKGROUND 
1.1 Receptor Tyrosine Kinases 
 
Receptor tyrosine kinases (RTKs) are transmembrane proteins that act 
as growth factor receptors and transduce signals from the extracellular 
environment to the cytoplasm and nucleus. Thereby, they regulate normal 
cellular processes such as survival, growth, proliferation, differentiation, 
adhesion, and motility.  There are 58 RTKs in the human genome, which have 
been classified into 20 families based on sequence similarities within the 
kinase domain and structural similarities within their extracellular regions 
(Robinson et al. 2000).  Activation of the kinase domains and further 
downstream signaling is enabled by receptor oligomerization, in most cases 
dimerization, as a consequence of ligand binding that brings two 
receptor‐chains together, or through ligand‐independent oligomerization 
processes (Schlessinger 2000, Ullrich and Schlessinger 1990).  The kinase 
domain, when activated, transfers a phosphate group from 
adenosine‐5'‐triphosphate (ATP) to selected tyrosine residues.  The 
phosphorylation occurs on the receptor at tyrosine residues in the activation 
loop, which stabilizes the active form of the receptor, but also on other tyrosine 
residues that, when phosphorylated, serve as docking sites for several 
downstream intracellular signaling proteins, that harboring Src Homology 2 
(SH2) or Phosphotyrosine binding (PTB) structural motifs, SH2 and PTB-
containing proteins, interact with the activated receptor (Pawson 2004) and 
transduce the signalling. The binding specificity of these intracellular signaling 
molecules is determined by the amino acid sequences surrounding each 
phosphotyrosine residue (Pawson 2004).  Abnormal overexpression or aberrant 
activation of RTKs has been associated to a variety of human cancers. 
 
1.1.1 TAM Family of Receptor Tyrosine Kinases 
1.1.1.1 TAM Receptors 
 
 The TAM family of RTKs includes three transmembrane receptors 
Tyro3, AXL and Mer that share unique adhesion‐molecule‐like extracellular 
region, characterized by two aminoterminal immunoglobulin (Ig)‐like domain, 
and two fibronectin‐type III (FNIII) repeats, as well as a conserved 
carboxy‐terminal KW(I/L)A(I/L)ES signature motif within their highly 
conserved intracellular kinase domain (O'Bryan et al. 1991) (Fig.1).  TAM 
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members share the vitamine K-dependent ligands Gas6 and Protein S (Linger 
et al. 2008).  Gas6 was first identified as a ligand for AXL in 1995 (Stitt et al. 
1995; Varnum et al. 1995). The related vitamin K-dependent anticoagulation 
factor, Protein S, was described as a ligand for Tyro-3 (Stitt et al. 1995). 
Although numerous subsequent studies confirmed that Gas6 binds to and 
activates all three members of the TAM receptor family, the validity of Protein 
S as a ligand for any of the TAM receptors became subject to extensive debate 
(Godowski et al. 1995; Mark et al. 1996; Nagata et al. 1996) and was 
established that AXL binds only to Gas6 and its affinity is also higher than its 
binding to Tyro3 or Mer.   Among the TAM family receptors, AXL and Tyro3 
have most similar genomic structure sharing the same number and size of 
exons (Linger et al. 2008).  In contrast AXL and Mer have the most similar 
tyrosine kinase domain amino acid sequence (Robinson et al. 2000). 
 
     
Figure.1. Illustrative picture of TAM Family RTKs (adapted from Linger et al.  2008). 
 
1.1.1.2 Expression Profile 
 
TAM receptor mRNA has been observed in embryonic tissues (Crosier 
et al., 1996; Faust et al. 1992; Graham et al. 1995; Lai and Lemke, 1991).  
Single, double, and even triple knockouts are viable without obvious signs of 
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developmental defect at birth (Lemke and Lu 2003; Lu and Lemke 2001; Lu et 
al. 1999). These data suggest that the TAM RTKs are largely non-essential for 
embryogenesis.  In adult tissues, Tyro-3, AXL, and Mer exhibit widespread 
distribution with overlapping but unique expression profiles. Tyro-3 is 
abundantly expressed in the nervous system, and is also found in ovary, testis, 
breast, lung, kidney, osteoclasts, and retina as well as in a number of 
hematopoietic cell lines including monocytes/macrophages and platelets 
(Angelillo-Scherrer et al. 2001; Lai et al. 1994; Lu and Lemke 2001; Prasad et 
al. 2006). AXL is expressed ubiquitously (O’Bryan et al. 1991), with notable 
levels found in the hippocampus and cerebellum (Bellosta et al. 1995) as well 
as monocytes/macrophages, platelets, endothelial cells, heart, skeletal muscle, 
liver, kidney, and testis (Angelillo-Scherrer et al. 2001; Graham et al. 1995; 
Neubauer et al. 1994).  Within the hematopoietic lineages, Mer is expressed in 
monocytes/macrophages, dendritic cells, NK cells, NKT cells, 
megakaryocytes, and platelets (Angelillo-Scherrer et al. 2001; Behrens et al. 
2003; Graham et al. 1994). High levels of Mer expression are also detected in 
ovary, prostate, testis, lung, retina, and kidney, while lower levels of Mer are 
found in heart, brain, and skeletal muscle (Graham et al. 1994, 1995; Prasad et 
al. 2006). 
 
1.1.1.3 Functions 
 
Functional studies have shown that the TAM receptors play an 
important role in the immune response by regulating the phagocytosis of 
apoptotic cells (Lemke and Burstyn Cohen 2010), the direct suppression of the 
inflammatory response (Rothlin et al. 2007), and the differentiation of natural 
killer cells (Caraux et al. 2006). In addition to their ability to regulate the 
immune response (Rothlin and Lemke 2010), these receptors have also been 
implicated in blood coagulation (Hafizi and Dahlback 2006), reproduction (Wu 
et al. 2008), diabetic nephropathy (Arai et al. 2008), and CNS function (Binder 
and Kilpatrick 2009).  In addition, Mer physiological role in clearance of 
retinal rods- and cones-shedded outer segments was described by functional 
ablation of Mer that resulted in the development of retinitis pigmentosa 
(Duncan et al. 2003; Camenisch et al. 1999). 
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1.1.1.4 TAM Receptors and Cancer 
 
In addition to the normal expression profile Tyro-3, AXL, and Mer also 
display ectopic or overexpression singly or in combination in numerous 
cancers, including myeloid and lymphoblastic leukemias, melanoma, breast, 
lung, colon, liver, gastric, kidney, ovarian, uterine, thyroid and brain cancers. 
Preclinical evidence indicates prominent involvement of Gas6 and TAM 
receptors in the pathobiology of cancer. Therefore, it is not surprising that 
different TAM receptors and Gas6 are overexpressed in different human tumor 
cell lines as well as in primary cancer tissues (Hafizi and Dahlback 2006; 
Linger et al. 2011). Several studies link expression levels of Gas6 and AXL to 
prognosis of cancer patients, while only scarce data exist on the prognostic 
impact of Tyro3, Mer and protein S.  Furthermore, AXL mediates resistance 
towards chemo- and targeted therapy including anti-VEGF or anti-EGFR 
therapy (Ye et al. 2010).  Tyro3 can transform cells in vitro, but its role in 
cancer is not well-defined like that of AXL.   In particular, Tyro3 can promote 
malignancy by inducing proliferation, which is at least partially mediated via 
PI3K signaling (Lan et al. 2000).  Mer is also involved in tumor biology, but 
data on this topic is still scarce.  Knocking down Mer in astrocytoma cell lines 
increases apoptosis and similar to AXL, Mer signals through p-Akt and 
through p-Erk1/2. 
 As already mentioned Gas6 is a common ligand for all 3 TAM 
receptors with different affinities (AXL>Tyro3>Mer).  The major source of 
Gas6 is Tumor Associated Macrophages.  Tumor cells in turn stimulate 
macrophages to upregulate Gas6 by expressing IL-10 and M-CSF, thereby 
inducing a vicious circle (Fig.2), because Gas6 through TAM receptors can 
foster cancer by promoting different hallmarks of malignancy.  The protumoral 
action of the Gas6-TAM receptor axis has been recognized, and disruption of 
this axis might also open up novel avenues in cancer treatment (Schmidt et al. 
2012).  Furthermore, there are reports suggesting that AXL acquires ligand-
mediated activation through the intrinsic presence of ligand Gas6 (Avilla et al. 
2011).  Though all three RTKs have a recognized role in tumorigenesis, it is 
AXL that has been established as potential cancer target, due to its over 
expression in several types of cancers (Graham et al. 1994) and its involvement 
in drug resistance.     
15 
 
 Figure 2. A Paracrine mode of TAM receptor activation (adapted from Schmidt et al. 2012) 
 
1.2 AXL Receptor Tyrosine Kinase 
 
The AXL gene localized at 19q13.1-13.2 (O'Bryan et al. 1991; Janssen et 
al. 1991), and it is known to have two splice variants, whose products are 
slightly different in size and molecular weight, resulting from alternative 
splicing of exon 10 and exon 11 (O’Bryan et al. 1991). Isoform one has nine 
amino acids more than isoform two. These amino acids are located within the 
ectodomain outside the transmembrane region on the carboxy‐terminal side of 
the FNIII domains. Isoform two lacks exon ten coding for these nine amino 
acids. The full‐length AXL protein contains 885 or 894 amino acids 
corresponding to the two isoforms, and the predicted molecular weight of AXL 
is about 98 KDa. However, three different forms resolve in SDS PAGE, i.e., 
140, 120 and 104 KDa that presumably correspond to fully‐, partially‐, and 
non-glycosylated forms, respectively (O'Bryan et al.1991).  AXL obtained its 
name from the Greek word “Anexelekto” meaning “uncontrolled”, and its 
transforming potential in human cancer has been suggested to be a result of 
overexpression rather than genetic alterations (O'Bryan et al.1991). Gas6 is the 
known and established ligand for AXL (Varnum et al. 1995).  
 
1.2.1 AXL in Cancer Pathogenesis and Progression 
 
 AXL was originally identified as a transforming gene involved in the 
progression of chronic myeloid leukemia (CML) to acute myeloid leukemia 
(AML) (Liu et al. 1988) and in chronic myeloproliferative disease (Janssen et 
al. 1991).  AXL has been shown to be overexpressed and to have mitogenic 
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and prosurvival roles in a broad spectrum of human malignancies, which has 
been summarised in Table 1.  
 
Table 1.Malignancies showing AXL overexpression (Modified from Verma et al. 
2011). 
 
S.NO CANCER TYPE REFERENCE 
1 Acute leukemia (ALL, AML) Rochlitz et al. 1999;  
Hong et al. 2008 
2 Astrocytoma Hutterer et al. 2008;  
Vajkoczy et al 2006 
3 Breast cancer Berclaz et al. 2001;  
Gjerdrum et al. 2010 
4 Colorectal Carcinoma Craven et al. 1995 
5 Esophageal Adenocarcinoma Hector et al. 2010 
6 Gastrointestinal stromal 
tumors 
Mahadevan et al. 2007 
7 Gastric cancer Wu et al. 2002 
8 Hepatocellular carcinoma He et al. 2010 
9 Kaposi sarcoma Liu et al. 2010 
10 Lung cancer Shieh et al. 2005; Linger et al. 2012 
11 Melanoma Quong et al. 1994 
12 Ovarian cancer Rankin et al. 2010 
13 Osteosarcoma Nakano et al. 2003 
14 Pancreatic ductal 
adenocarcinoma 
Koorstra et al. 2009 
15 Renal cell carcinoma Gustafsson et al. 2009 
16 Prostate cancer Sainaghi et al. 2005;  
Paccez et al. 2013 
17 Thyroid cancer Ito et al. 1999; Avilla et al. 2011 
18 Uterine endometrial cancer Sun et al. 2003 
 
 
Both AXL and its ligand Gas6 are frequently overexpressed and predict 
poor prognosis (Hutterer et al. 2008).  Moreover, AXL affects multiple cellular 
behaviors required for neovascularization, such as endothelial proliferation, 
migration, survival, and tube formation in vitro, and regulates angiogenesis in 
vivo (Holland et al. 2005).  Though AXL is a transmembrane protein, a soluble 
form of AXL (sAXL), consisting of the proteolytically released extracellular 
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domain is present in human serum (Budagian et al. 2005; Balogh et al. 2005).  
Gas6 is also present at low concentrations in circulation, and in both mouse and 
human serum Gas6 circulates in complex with sAXL (Budagian et al. 2005; 
Balogh et al. 2005).  The TAM receptor involvement in thyroid carcinoma with 
prime focus on the tumor driving ability of AXL was described (Avilla et 
al.2011).  This particular study showed that human PTC/ATC cells and 
samples, but not normal thyroid, constitutively express AXL.  Moreover, the 
critical role of AXL in mediating thyroid cancer cell proliferation, survival, 
invasiveness and experimental tumor growth formation in nude mice was 
demonstrated, suggesting AXL and its signalling axis, as a potential therapeutic 
target in thyroid carcinoma. To date, no activating mutations in AXL have been 
reported in cancer; however, dysregulation of AXL-mediated signaling 
pathways plays an important role in oncogenic transformation.  
  
1.2.2 AXL mediated signalling pathways 
 
AXL is a proto‐oncogene whose overexpression can transform cells 
even in the absence of ligand, and it is believed that AXL transforming 
potential is due to activation and overexpression of the receptor rather than any 
genetic alterations (O'Bryan et al. 1991; Janssen et al. 1991).  AXL activation 
in tumor cells has been suggested to follow an autocrine/paracrine pathway 
(Dirks et al. 1999; Avilla et al. 2011), and AXL transforming capacity also 
seem to be cell‐specific (Burchert et al. 1998).  Gas6 activation of AXL results 
in phosphorylation of three known consensus tyrosine residues kinase region 
that recruit various signaling molecules: tyrosine 779 (pYALM; 
phosphatidylinositol 3‐kinase (PI3K) binding site), 821 (pYVNM; PLCγ-, 
PI3K-, c‐Src-, Lck-, Grb2-binding site), and 866 (pYVLC-, PLCγ-binding site) 
(Braunger et al. 1997; Weinger et al. 2008).  Activation of AXL stimulates 
both proliferative and anti-apoptotic signalling, including PI3K/AKT and 
MAPK/ERK pathways (Linger et al. 2008).    Several lines of evidence suggest 
that anti‐apoptotic effect are the most relevant effects of Gas6-mediated AXL 
signaling (Goruppi et al. 1996; 1997; Melaragno et al. 2004).  It is speculated 
that AXL-Gas6 axis can generate two different context‐dependent PI3K 
signaling pathways; one where PI3K binds directly to AXL resulting in 
survival, and one where PI3K binds indirectly to AXL through Grb2 leading to 
proliferation (Weinger et al. 2008). However Ras/Erk axis mediated growth 
and proliferation has also been reported (Fridell et al. 1996; Stenhoff et al. 
2004; Sainaghi et al. 2005).   
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1.3 Targeting a Tyrosine Kinase Receptor 
 
 RTK activation regulates many key pathways leading to malignant 
phenotype; consistently, dysregulation of RTKs has been shown to correlate 
with the development and progression of numerous cancers.  Therefore RTKs 
have become an attractive therapeutic target.  On a broad view there are two 
types of RTK targeting approach, using agents with a capability of targeting 
one or a few targets and using those with a broad one (multiple targets).  The 
first two approaches are carried out using Small Molecule Inhibitors: E.g. 
Imatinib (Gleevec), which targets the ATP binding site of the kinases, or 
Antireceptor Antibodies: E.g. Herceptin (Trastuzumab), which targets HER2 
(Fig.3).  Both these approaches hold their own positives and negatives. For 
instance, targeting a single target has been successful when the target controls 
the majority of the critical oncogenic signalling.  However, this narrowed 
targeting is effective only for a short-term, as several clinical studies have 
shown the resistance acquired to the single targeting agent.  On the other hand, 
agents targeting multiple pathways simultaneously are more effective than 
agents with narrow selectivity, they also decrease the likelihood of resistance 
development, but the toxicity and side effects in this approach are generally 
more than the previous one.   
 
 
 
Figure3:  Strategies to target RTK’s (adapted from Bavcar and  Argyle 2012) 
 
 With the rapid rise of tumor resistance, combinatorial anticancer 
therapies have gained favour over single molecule inhibition.  In this regard, 
HSP90 inhibitors have rapidly emerged as a class of promising drugs that can 
target multiple oncogenic pathways simultaneously. HSP90 is a highly 
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conserved chaperone protein involved in essential cellular functions such as 
protein folding and cell signalling in both stressed and unstressed cells. In the 
past decade, a large number of oncogenic client proteins have been identified 
to associate with HSP90 and contribute to malignant transformation, in which 
receptor tyrosine kinases are the notable ones.   Hence, oncogenic RTKs that 
are client of HSP90 are targetable through inhibiting HSP90.   
Several reports documented the dependence of cancer cells on 
molecular chaperones, such as Hsp70 and Hsp90, and this notion has added 
chaperone inhibitors to the arsenal of anticancer drugs (de Billy et al. 2009; 
Whitesell and Lindquist 2009). Hsp90 inhibitors are in fact already in clinical 
trials, with promising results (Taldone et al. 2008; Hwang et al. 2009).   
 
1.4 Molecular Chaperones 
 
Cells harbour a set of proteins called molecular chaperones which assist 
folding and prevent the aggregation of misfolded proteins during de novo 
protein synthesis as well as under stress conditions such as high temperature 
(Young et al. 2004).  They are ubiquitous proteins and are life-guards of the 
living cells by preventing the protein misfolding and aggregation, which is 
otherwise toxic to the cell.  Molecular chaperones perform basic and essential 
cell functions, such as facilitating newly synthesized polypeptides to fold 
properly into their biologically native structure, assisting denatured protein in 
refolding, and preventing protein aggregation.  Misfolding of any cellular 
protein usually results in the exposure of hydrophobic surfaces that in its native 
state are normally buried in the interior. Hydrophobic surfaces when exposed 
tend to associate with those from other proteins generating aggregation. 
Molecular chaperones bind such exposed surfaces through their own exposed 
hydrophobic binding sites and assist in refolding. Molecular chaperones 
increase the yield of folding reactions by amplifying the number of productive 
folding pathways (Frydman 2001; Hartl 1996; Buchner 1996).   
Chaperones are divided into four major families, Hsp90, Hsp70, Hsp60, 
and Hsp20, based on their relative molecular mass (Calderwood et al. 2006; 
Jego et al. 2010), while additional novel families include Hsp110 and Hsp170 
(Easton et al. 2000).  To date, more than 200 HSP client proteins have been 
identified involving nearly all fundamental cellular activities and processes, 
including cell growth, proliferation, and cell survival (Jego et al. 2010). 
Interestingly, many cancer-associated proteins have been reported as HSP 
clients, likely as a mechanism for promoting oncogenic transformation. 
Moreover, in order to survive under the harsh conditions within the tumor 
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microenvironment, cancer cells typically become dependent on stress-inducible 
HSP’s.  Therefore, targeting HSPs would result in simultaneous inhibition of 
multiple signaling pathways responsible for modulation of various events 
involved in cancer progression for a broad range of tumor types, such as 
neoplastic growth, sustained angiogenesis, chemotherapeutic resistance, 
evasion of cell death, and ultimately, invasion and metastasis (Barginear et al. 
2008).   
 
1.4.1 Heat Shock Protein 90 
 
The HSP90 is an ubiquitously expressed cellular protein that constitutes 
1–2% of the total protein load (Csermely et al. 1998; Crevel et al. 2001).  Five 
HSP90 isoforms have been identified so far that include cytoplasmic HSP90α- 
and β-isoforms, endoplasmic reticulum localized glucose regulated protein 94 
(GRP94), mitochondrial tumor necrosis factor receptor-associated protein 1 
(TRAP1) and membrane-associated HSP90N (Pearl and Prodromou 2000).  
Eukaryotic Hsp90 chaperones are the key players in the signal transduction 
networks of the cell, interacting with numerous client substrates in a complex 
system together with Hsp70 chaperones and a large number of co-chaperones.   
 
1.4.2 Hsp90 Structure 
 
The HSP90 protein consists of three highly conserved domains: an N-
terminal nucleotide binding domain (NBD), a middle domain (MD) and a C-
terminal dimerization domain (DD) necessary to form Homodimeric 
complexes (Fig.4). 
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Figure 4: Structure of the Hsp90 dimer. The numbering 1–732 indicates the approximate 
positions in the amino acid sequence of the human protein that define its functional domains. 
‘CR’ refers to a charged region which serves as a flexible linker between the N-terminal and 
middle domains. The locations where ATP and inhibitors (small molecules) bind Hsp90 and 
modulate its function are indicated.  
 
 Three-dimensional crystallization structures revealed a two layer α/β 
sandwich structure in which the helixes delimit a pocket extending from the 
surface to the buried face of highly twisted antiparallel β−sheet. In the human 
structure, this pocket was found to be the binding site for ATP and for the 
macrocyclic antitumour agent geldanamycin, whose binding to Hsp90 had been 
shown to disrupt productive complexes of Hsp90 with client protein such as 
kinases and steroid hormone receptors (Whitesell et al. 1994; Chavany et al. 
1996).  The middle domain consists of a large N-terminal αβα (αhelix-βsheet-
αhelix) domain connecting to a small αβα domain at the C-terminal via series 
of short α−helixes in a tight coil. The middle segment is the major site for 
client protein interactions, with a conserved hydrophobic patch centred on Trp 
300 and an unusual amphipatic protrusion formed by residues 327-340.  The 
middle segment also contributed a key catalytic lysine residue that would 
interact with the γ−phosphate of an ATP molecule bound in the N-terminal 
domain (Meyer et al. 2003). The C-terminal domain is essential for Hsp90 
dimerization. The dimer interface is formed by a pair of helixes at the C-
terminal end of the domain packing together to create a four-helix bundle. The 
Cterminal domain presents the MEEVD motif implicated in binding to 
cochaperones with tetratricopeptide repeat (TRP) domains (Young et al. 1998). 
 Co-chaperones, such as HOP, CDC37, p23, Aha1 and PPIase, play an 
important role in client protein maturation and modulation of ATPase activity. 
Co-chaperones also recruit specific client proteins to HSP90 and/or stabilize 
HSP90 in an ATP-bound state to prolong the half-life of the mature multi-
chaperone complex (Wandinger et al. 2008).  ATP hydrolysis alters HSP90 
structure and promotes its chaperone function. Therefore, in cells, HSP90 
generally exists in 2 conformations – an active “open” conformation that is in 
an ATP bound state during client protein binding, and an inactive “closed” 
conformation (Buchner 1999). 
 
1.4.3 Hsp90 chaperone cycle 
 
Hsp90 function in client activation and maturation is highly dependent 
on binding and hydrolysis of ATP (Obermann et al. 1998; Panaretou et al. 
1998) which drives a dynamic conformational cycle that involves interactions 
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with the Hsp70 system and an increasing number of co-chaperones.  The 
HSP90 chaperone cycle consists of transitions between open and closed protein 
conformations (Kamal et al. 2004). Throughout each cycle, the transition 
between open and closed states allows for the rearrangement of different co-
chaperones that associate with HSP90. To begin the cycle, the two N-terminal 
domains of the dimer are in a separated, open state, which is maintained 
through interaction with Hop at both the N-terminal and C-terminal domains 
(Richter et al. 2008; Prodromou et al. 1999; Richter et al. 2003). A client 
protein is recruited to HSP90/HOP via the HSP70/HSP40 co-chaperone 
complex, which associates with HSP90 through the interaction of HSP70 with 
Hop (Pearl et al. 2008). While in this intermediate complex, the client protein 
is transferred from HSP70 to the middle domain of HSP90. At this point, ATP 
is bound to each of the N-terminal binding pockets. Next, Hop disassociates 
from the HSP90 complex, due to reduced affinity following binding of ATP 
and the co-chaperone p23 (Li et al. 2011; 2012). In this mature complex, the N-
terminal and middle domain are brought together to form the closed state of the 
chaperone complex. At this stage, both HSP90 and p23 facilitate folding of the 
client protein (Li et al. 2011; 2012). To complete the cycle, additional co-
chaperones, such as aha1 (activator of HSP90 ATPase) and the peptidylprolyl 
cis-trans isomerases Cpr6/Cyp40, bind to the chaperone complex and induce 
ATP hydrolysis (Panaretou et al. 2002; McLaughlin et al. 2002). Conversion of 
ATP to ADP + Pi allows the HSP90 dimer to reopen, and the newly or refolded 
client protein disassociates from the chaperone complex. Upon returning to its 
open state, HSP90 reassociates with Hop in place of p23, and thus completes 
the cycle (Hessling et al. 2009). 
In particular, HSP90 role in the folding and maturation of various client 
proteins, as well as the renaturation of misfolded proteins (Shen et al. 2005; 
Chiosis et al. 2001), makes them potential targets for many diseases ranging 
from the disruption of multiple signaling pathways associated with cancer  to 
the clearance of protein aggregates in neurodegenerative diseases.   In fact, 
inhibitors of Hsp90 are the only cancer chemotherapeutic agents known to 
disrupt all six hallmarks of cancer simultaneously (Guo et al. 2006).  Previous 
studies show that level of Hsp90 is higher in various malignant cell lines and 
cancer cells compared to normal cells (Whitesell and Lindquist 2005). 
 
1.4.4 Hsp90 - A Potential Cancer Therapeutic Target 
 
HSP90 function maintains the cancer phenotype by helping cancer cells 
to overcome environmental stress, proteotoxic stress, nutrient insufficiency, 
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redox state, and the necessity to escape from immune destruction (Neckers and  
Workman 2012).  Many of its client proteins are signaling oncoproteins that 
represent nodal points in multiple oncogenic signaling pathways (Modi  et al. 
2011; Neckers and  Workman 2012).  Examples of client proteins of HSP90 
that play an important role in cancer include the human epidermal growth 
factor receptor 2 (HER2), mutant epidermal growth factor receptor (EGFR), 
the BCR-ABL fusion protein, BRAF, the serine-threonine protein kinase 
AKT/PKB, c-MET, as well as the steroid hormone receptors (estrogen receptor 
and androgen receptor). The selected examples of HSP90 client protein 
pathways involved in sustaining cancer phenotype is shown in Figure 5.  Other 
than mediating the oncogenic signalling cascade through chaperoning the 
signal transducing oncoproteins, HSP90 also involved in other hallmark 
processes of cancer, including induction of angiogenesis, resistance to cell 
death (anti-apoptosis), and promotion of metastasis.  For instance, HSP90 
influences angiogenesis by chaperoning hypoxia inducible factor-1α (HIF-1 
alpha) and vascular endothelial growth factor receptor (VEGFR), in addition to 
governing nitric oxide synthase upregulation. HSP90 chaperones client 
proteins that are anti-apoptotic, including AKT and survivin. Thus, inhibition 
of HSP90 could lead to increased apoptosis and enhanced anticancer activity. 
Also, HSP90 chaperoning promote metastasis through matrix 
metalloproteinase-2 (MMP-2) activation (Hanahan and Weinberg 2011; Basso 
et al. 2002).  Other client proteins of HSP90 that play a role in cell signaling 
processes include IL6R (JAK/STAT pathway), FAK (integrin pathway), CDK 
4, 6, 9 (cell cycling), IkB kinases (NFkB pathway) and APAF-1 (apoptosis) 
(Khong and Spencer 2011). 
 The role of HSP90 in malignancy is mediated by its ability to control 
the stabilization of its oncogenic client proteins, as well as regulate their 
activated states.  Cancer cells that depend on these HSP90 dependent 
oncoproteins are sensitive to HSP90 inhibition (Workman and Powers 2007). 
Thus blockade of many key cancer causing pathways upon the disruption of the 
HSP90 chaperone complex association with the client, results in client proteins 
polyubiquitination and proteasome-dependent degradation (Neckers et al. 
1999; Xu et al. 2005).  Recent studies indicate that combination of low dose 
Hsp90 inhibitors with conventional chemotherapeutic agents or radiation 
provides an effective strategy in cancer therapy.  One concern is that HSP90 
inhibitors may act as inducers of all heat shock proteins, including Hsp40 and 
Hsp70, via activation of heat shock factor 1 (HSF-1) (Bagatell et al. 2000; 
Bagatell and whitesell 2004).  Therapies that combine Hsp90 and Hsp70 
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inhibition, for instance, might be necessary to improve efficacy of either 
treatment alone (Guo et al. 2005). 
 
                                             
 
Figure 5: Selected examples of HSP90 client protein pathways involved in survival and anti-
apoptosis of tumor cells. JAK – Janus family of tyrosine kinases; STAT – Signal transducers 
and activators of transcription; MAPK/ERK – Mitogen activated protein kinase, Extracellular 
signal-regulated kinase; PDK – Phosphoinositide-dependent kinase. (Hong et al. 2012 Cancer 
Treatment Review) 
 
 
1.5 HSP90 Inhibitors 
 
As already mentioned, HSP90 chaperone consists of three domains: (i) 
the amino terminal region (N-domain) that contains the ATP, drug-binding site, 
and co-chaperone interacting motifs, (ii) a middle (M) domain that participates 
in forming active ATPase and also serves as a docking site for client proteins 
and cochaperones, and (iii) the carboxy terminal region (C-domain) that 
contains a dimerization motif, a second drug-binding site, and interaction sites 
for cochaperones (Ali et al. 2006; Prodromou & Pearl 2003).  Thus far, all the 
HSP90 inhibitors in clinical trials work by inhibiting the ATPase activity of 
HSP90 by binding the drug-binding site on the N domain (Janin 2010; Taldone 
et al. 2009). In general, they can be classified into first-generation inhibitors, 
based on their similarity to Geldanamycin, or second-generation small 
molecule synthetic inhibitors like resorcinol or purine derivatives. 
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1.5.1 Geldanamycin (GA) Derivatives - The First-Generation HSP90 
Inhibitors  
 
Geldanamycin (GA) is an ansamycin antibiotic first isolated from 
streptomyces hygroscopicus (DeBoer et al. 1970).  The effects observed from 
the naturally occurring compound has opened the gateway for HSP90 inhibitor 
development, as this compound showed destabilizing effects on some HSP90 
clients in the preclinical studies (Workman et al. 2007). It has been 
demonstrated through cocrystallographic study that GA competes with ATP 
binding to the nucleotide binding pocket on the N-terminal domain of HSP90, 
thereby inhibiting its ATPase activity (Stebbins et al. 1997; Sittler et al.2001).  
As Geldanamycin exhibited severe hepatotoxicity, its use in the clinic was 
discontinued. However, derivatives of geldanamycin proved better 
pharmacological properties and successfully entered into clinical trials as first 
HSP90 inhibitors.  The primary analogs of GA include Tanespimycin (17-
allylamino-17-demethoxygeldanamycin, 17-AAG), Alvespimycin (17-
dimethylaminoethylamino-17-demethoxygeldanamycin, 17-DMAG), 
retaspimycin or IPI-504 (17-Allylamino-17-Demethoxygeldanamycin 
Hydroquinone Hydrochloride).  
 
1.5.1.1 Tanespimycin 
17-allylamino-17-demethoxygeldanamycin (17-AAG), a geldanamycin 
derivative, was the first HSP90 inhibitor to be evaluated in humans. 17-AAG 
was derived by substituting the nonessential methoxy group on the C-17 of the 
quinine ring in GA with an amino group. 17-AAG retained the antitumor 
properties of GA with a more favourable and acceptable safety profile (Solit et 
al. 2002; de Candia et al. 2003). 17-AAG entered clinical trials in cancer 
patients in the US and UK (Sausville et al. 2003; Goetz et al. 2005). Although 
initial trials were disappointing, development of an improved formulation of 
17-AAG by Kosan Pharmaceuticals named Tanespimycin (KOS-953), 
displayed a promising clinical relevance. Under this new formulation, 
impressive clinical activity were noted in trastuzumab-refractory HER2-
positive breast cancer and in multiple myeloma, especially in bortezomib 
refractory patients (Modi et al. 2011).  These data prompted a phase III trial of 
tanespimycin plus bortezomib for this indication (ClinicalTrials.gov identifier: 
NCT00514371).  Despite its promising activity in clinical studies, the presence 
of the benzoquinone sub-group in the structure of tanespimycin may contribute 
to the drug’s greater hepatic toxicity, and constitute a mechanism of drug 
resistance in patients with mutated/altered NQO1 (Neckers and Workman 
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2012). Indeed, tanespimycin’s clinical limitations are modest bioavailability, 
instability and toxicity (Workman et al. 2007). 
 
1.5.1.2 Alvespimycin 
17-Desmethoxy-17-N,N-Dimethylaminoethylaminogeldanamycin (17-
DMAG) was formed as a result of substituting the C-17 methoxy group of GA 
with N-N-dimethylethylamine. This formulation has increased water solubility 
and equal or better potency compared to 17-AAG (Hollingshead et al. 2005). 
This is the second HSP90 inhibitor to enter clinical trials and is less sensitive to 
and less dependent on NQO1 with better pharmacokinetic properties (Neckers 
and Workman 2012) and fewer side-effects (Workman et al. 2007; Li et al. 
2009). Alvespimycin retained tanespimycin’s activity, or even greater. In a 
study of alvespimycin administered to 25 patients with advanced malignancies, 
complete response (CR) occurred in one patient with castration resistant 
prostate cancer (CRPC), partial response (PR) in one patient with metastatic 
melanoma, and stable disease (SD) >6 months occurred in three patients with 
chondrosarcoma, CRPC and clear cell renal cancer respectively (Pacey et al. 
2011). However, alvespimycin, like tanespimycin, may be most beneficial in 
combination with client protein inhibiting drugs, such as trastuzumab. A recent 
phase I study of such combination showed a partial response in a HER2+ 
breast cancer patient and stable disease >6 months in 6/28 Patients (Jhaveri et 
al. 2012). 
 
1.5.1.3 Retaspimycin 
 IPI-504 is a water soluble, hydroquinone hydrochloride salt derivative 
of 17-AAG, and the hydroquinone form (IPI-504) is in redox equilibrium with 
the quinone form (17-AAG).  IPI-504, when subjected to phase II trial in 
refractory NSCLC showed a promising response rate in patients having ALK 
rearrangement but not in those without ALK rearrangement (Sequist et al. 
2010).  The high degree of sensitivity of EML4-ALK to HSP90 inhibition by 
IPI-504 suggests that patients having cancer subtypes with EML4-ALK as a 
key oncogenic driver may be more sensitive to HSP90 inhibition (Normant et 
al. 2011).  Promising activity was also seen in GISTs, which formed the basis 
of the phase III RING (Retaspimycin in GIST) trial.  Regardless of the 
antitumor effect seen, due to the high mortality rate in the IPI-504 treatment 
arm, this trial was recently suspended. IPI-493, a similar derivative in oral 
form, has entered in phase I study. 
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1.5.2 Synthetic Small Molecules – The Second and Third Generation 
HSP90 Inhibitors 
 
 Synthetic molecules have been designed to evade the toxic side effects 
attributed to the benzoquinone group on geldanamycin-based molecules.  
These compounds bind the N-terminal ATPase site of HSP90 with higher 
affinity than the natural nucleotides and prevent HSP90 from cycling between 
its ADP- and ATP-bound conformations. The first group of these agents is the 
purine scaffold series, based on the prototype PU3 developed by the Chiosis 
laboratory (Chiosis et al. 2001).  Purines such as CNF2024/BIIB021, MPC-
3100, and PU-H71 and purine-like analog Debio-0932 (CUDC-305) 
demonstrate insensitivity to multidrug resistance, high aqueous solubility, and 
oral bioavailability (Chiosis et al. 2002; Rodina et al. 2007).  CNF2024, an 
orally available 9-benzyl purine derivative developed by Conformal 
Therapeutics, following its clinical activity and favourable tolerability in the 
phase I trials in chronic lymphocytic leukemia (CLL), lymphomas, advanced 
solid tumors, and most recently in breast cancer (Jhaveri et al. 2012) has 
entered phase II studies.   
Several other small molecule HSP90 inhibitors have recently been 
reported in the clinical setting including AUY922, AT13387, STA9090, and 
MPC3100. In a phase I study involving treatment with AUY922, extended 
disease stabilization in a subset of advanced solid tumor patients was noted 
(Samuel et al. 2010).  AT13387 in vitro has been the longest-acting HSP90 
inhibitor to date, suppressing client proteins longer than 7 days.  Beside these, a 
new class of compounds that target HSP90’s C-terminal domain have been 
developed, and investigators have been able to increase the affinity of these 
molecules for HSP90. A family of coumarin antibiotics, the most notable of 
them being DB01051 (novobiocin), binds to the C-terminal domain of HSP90 
and disrupts the HSP90 chaperone complex, resulting in HSP90 client protein 
degradation similar in action to the compounds that bind to the N-terminus, but 
with less degradative ability (Marcu et al. 2000). Advantages of HSP90 
inhibitors that target the C-terminal domain (C-terminal inhibitors) include less 
robust activation of heat shock factor 1 (HSF1), which induces HSP90 
transcription.  However, concentrations of novobiocin high enough to inhibit 
HSP90 have not been reached in vivo, thus several other derivatives of 
novobiocin such as triazole containing analogues are in development (Peterson 
and Blagg  2010). 
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2. AIM OF THE STUDY 
 
AXL plays a significant role in pathogenesis and progression of human 
cancer and in anti-cancer drug resistance.  Our previous observations that AXL 
is deregulated in Thyroid cancer and its inhibition results in decreased 
proliferation, invasiveness and experimental tumor growth formation in nude 
mice supports several other reports described for different types of cancers.  
HSP90 is a critical player in maintaining the cancer phenotype by its 
ability to control the stability of its oncogenic client proteins. HSP90 inhibition 
causes depletion of multiple oncogenic client proteins, leading to the blockade 
of many key cancer causing pathways.  The greatest therapeutic benefits with 
HSP90 inhibitors could derive from targeting tumors that have its client 
proteins as oncogenic drivers. 
 On aiming to devise a strategy to target the receptor tyrosine kinase 
AXL, we opted to use the HSP90 inhibition approach based on our observation 
that HSP90 inhibitors effectively downregulate AXL protein levels. This thesis 
will contribute significantly in validating AXL as a novel client of HSP90, an 
ongoing target for the treatment of cancer.   
 
In particular, the major focus of this thesis will address the following topics: 
 
1. Validation of AXL as a Novel client of HSP90.  
 
2. Molecular mechanism of 17-AAG induced AXL degradation. 
 
3. The effect of 17-AAG on AXL driven signalling and biological 
activity. 
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3. MATERIALS AND METHODS 
 
3.1 Reagents and Antibodies 
 
17-AAG, Radicicol and MG132 were purchased from Calbiochem 
(Merck KGaA, Darmstad, Germany).  Lactacystin, Ammonium chloride, and 
Chloroquine were purchased from Sigma (St. Luis, MO, USA).  Endo H and 
Peptide-N-Glycosidase (PNGase) were from New England Biolabs (Ipswich, 
MA, USA). Anti- HSP90 (#SPA-835) and anti-HSP70 (#SPA-810) were 
purchased from Stressgen biotechnologies (Victoria, BC, Canada).  Anti-AXL, 
anti-Tyro3, anti-myc, anti-HA antibodies used in western blot and 
immunoprecipitation experiments were from Santa Cruz Biotechnology (Santa 
Cruz, CA, U.S.A). The anti-AXL antibody directed to AXL extracellular 
domain and anti-phospho AXL, specific to tyrosine 779, were from R&D 
Systems (Abingdon, UK).  Anti-phosphotyrosine antibody (4G10) was from 
Upstate Biotechnology (Lake Placid, NY, USA) and anti-DYKDDD tag 
(FLAG epitope) antibody from Cell signalling Technologies (Beverly, MA, 
USA). Secondary antibodies coupled to horseradish peroxidase were from 
BioRad (Munchen, Germany). 
 
3.2 Cell Lines and Transfection Procedures 
 
HeLa cells were from American Type Culture Collection (ATCC, 
Manassas, VA). Human thyroid papillary cancer cell line TPC1, and anaplastic 
thyroid cancer cell lines 8505C and  CAL62 have been previously described 
(Avilla et al. 2011) and were grown in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% fetal calf serum (Life technologies, GIBCO, 
Carlsbad, CA, USA). Transient transfections were carried out by premixing 
each plasmid (1-1.5µg) with Fugene6 (Roche, Basel, Switzerland), and the 
mixture was added to cells at 70% confluency.  Cells were continually cultured 
in the same medium for 48 hours until lysis or further treatments. 
 
3.3 Western Blotting and Immunoprecipitation 
 
Protein lysates were prepared according to standard procedures. Cells 
were lysed at 4ºC in a buffer containing 50 mM N-2-hydroxyethylpiperazine-
N'-2-ethanesulfonic acid (HEPES; pH 7.5), 1% (vol/vol) Triton X-100, 150 
mM NaCl, 5 mM EGTA, 50 mM NaF, 20 mM sodium pyrophosphate, 1 mM 
sodium vanadate, 2 mM phenylmethylsulphonyl fluoride (PMSF), and 1 µg/ml 
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aprotinin. Lysates were clarified by centrifugation at 10,000 x g for 20 min. 
Lysates containing comparable amounts of proteins, estimated by a modified 
Bradford assay (Bio-Rad, Munchen, Germany), were subjected to Western 
blot. For immunoprecipitation, 1mg of lysate was incubated with appropriate 
antibody for 3 hrs or overnight and then with the slurry of protein A/G-
sepharose for 1 hr at 4ºC. Antigen-Antibody-Bead complexes were centrifuged, 
washed extensively using wash buffer (20 mM Tris-Hcl pH7.4, 150 mM Nacl, 
Triton 0.1%), resuspended in Laemmli buffer (60 mM Tris-Cl pH 6.8, 2% 
SDS, 10% glycerol, 5% β-mercaptoethanol, 0.01% bromophenol blue), boiled, 
resolved by SDS-PAGE, transferred to nitrocellulose membrane and probed 
with primary antibodies followed by secondary antibodies coupled to 
horseradish peroxidase.  The proteins were detected with the enhanced 
chemiluminescence kit (Amersham Pharmacia Biotech, Little Chalfort, UK). 
 
3.4 Plasmids and Constructs 
 
We used pCDNA 4TOA His/myc (Life technologies, Invitrogen, 
Carlsbad, CA, USA) and pFLAG5a (Sigma) vectors to subclone the full 
length AXL by PCR amplification.  The truncated mutant AXL-EC has been 
previously described (Avilla et al. 2011), comprises the extracellular and 
transmembrane domain of the receptor, 1 to 508 amino acids (NM_001699) 
and it has been obtained from its full length construct by PCR with specific 
primersF:GAATTCGCTGGGAGCCCAACAACTT,  R: AAGCTTCCCA 
GGCTGTTCAAGGTAGC) and subcloned using ECORI and HINDIII into 
pFLAG5a vector.  PCDNA 3.1 CHIP-myc and CHIP-TPR-myc (K30A) 
vectors were a kind gift of L. Neckers. PCDNA-HA-Ubiquitin (Ub-HA) 
vector was a kind gift of S. Giordano. HSP90-HA (García-Cardeña et al. 
1998), expressing the Hsp90β wt cDNA in pcDNA3, was obtained from 
Addgene non-profit plasmid repository, as "Addgene plasmid 22487". 
 
3.5 Biotinylation of Surface Proteins 
 
Cells grown around 70% confluence were washed twice with ice-cold 
PBS with 10 mM ca2+ and 1 mM Mg2+ and surface proteins were labelled for 
30 minutes using 1 mg/ml EZ-link NHS-SS-biotin (Pierce Chemical Co., 
Rockford, IL). All manipulations were carried out on ice to avoid the 
internalization at these steps. The unreacted biotin was removed by washing 
with 50mM NH4Cl in PBS, and cells were lysed in the RIPA buffer (50 mM 
Tris-Hcl pH 7.4, 150 mM Nacl, 1% Triton, 0.5% Sodium deoxycholate, 0.1% 
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SDS and 1 mM EDTA). Comparable amount of proteins were incubated 
overnight with Streptavidin beads (Pierce Chemical), which were then 
thoroughly washed, denatured and analyzed by Western blot with anti-AXL 
antibodies.  The assessment of surface protein turnover by surface 
Biotinylation and chase was performed as previously described (Gottardi et al. 
1995), the biotin labelling was performed as above and then cells were allowed 
to grow under normal condition or with treatment, which are harvested at the 
appropriate time points.   
 
3.6 [35S]Methionine labelling and pulse chase analysis of AXL 
 
CAL62 cells plated in 60mm dish at 70% confluence were starved for 1 
hr in 1.5 ml of methionine/cysteine-free medium, metabolically labelled with 
200 µci of 35S methionine for 20 mins in methionine/cysteine-free medium 
(pulse), washed free of unbound radioactive amino acids, and incubated in 
prewarmed complete medium (chase) in the presence of vehicle or 17-AAG 
(500 nM). At the indicated time points, the cells were disrupted in ice-cold 
lysis buffer and comparable amount of whole cell extract were 
immunoprecipitated with anti-AXL antibody. Proteins were subjected to SDS-
PAGE. Labelled proteins were visualized by autoradiography. 
 
3.7 Immunofluorescence analysis 
 
To assess the plasma membrane localized AXL  through 
immunofluorescence, cells plated on fibronectin-coated glass coverslips were 
subjected to 17-AAG treatment for 8 hrs, fixed with 4% paraformaldihyde, 
blocked using PBS-BSA (1%), incubated with 1:50 dilution of 1µg/µl anti-
AXL antibody (R&D Systems) for 2 hrs at room temperature, followed by a 
1:1000 diluted rhodamine conjugated anti-goat secondary antibody (Jacksons 
immunoresearch Europe Ltd, Oaks Drive Newmarket, Suffolk, UK) for 30 
min. Analysis was performed using a Zeiss LSM 510 Meta confocal 
microscope. 
 
3.8 Luciferase Activity Assay 
 
Approximately 1×106 HeLa cells were transiently co-transfected with 
AXL and the AP1-Luc vector (Stratagene, Garden Grove, CA, USA) 
containing six AP1-binding sites upstream from the Firefly luciferase cDNA. 
Twenty-four hours after transfection, cells were serum-starved and the 
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indicated concentration of 17-AAG or vehicle was added. Cells were harvested 
48 hrs after transfection. 10 ng pRL-null (a plasmid expressing the enzyme 
Renilla luciferase from Renilla reniformis) served as an internal control. Firefly 
and Renilla luciferase activities were assayed using the Dual-Luciferase 
reporter system (Promega Corporation, Madison, WI, USA) and expressed as 
percentage of residual activity compared with cells treated with vehicle. Light 
emission was measured by using a Berthold Technologies luminometer (Centro 
LB 960) (Bad Wildbad, Germany) and expressed as ratio of Firefly and Renilla 
luciferase activities. The ANOVA multiple comparison test was used to assess 
statistical significance of luciferase assay, and the InStat3 Graphpad Software 
(La Jolla, CA, USA) was used. 
 
3.9 Nickel affinity His-tagged protein purification under denaturing 
conditions  
 
 HeLa cells 48hrs post-transfected with His tagged AXL (sub-cloned 
in pCDNA 4 TO A His/myc) were harvested and lysed with Buffer A (6 M 
Guanidium Hcl, 100 mM Sodium phosphate buffer pH.8, 10 mM Tris Hcl 
pH. 8 and 30 mM Imidazole and 10 mM beta-Mercaptoethanol). The lysate 
was rocked with Ni-NTA Agarose beads (Qiagen) for 4 hrs to overnight. The 
beads were collected and washed with Buffer B (8 M Urea, 100 mM 
Phosphate buffer pH.6.3, 10 mM Tris Hcl pH.6.3, 10 mM beta-
Mercaptoethanol and 0.2 % Triton X 100), and eluted in Buffer E (200 mM 
Imidazole, 150 mM Tris Hcl pH 6.7, 30% Glycerol, 5% SDS and 720 mM 
Beta-Mercaptoethanol). Proteins were resuspended in sample buffer (2X) and 
subjected to SDS PAGE followed by western blotting. 
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4. RESULTS 
4.1 PART I – Validation of AXL as a novel client of HSP90 
4.1.1 Sensitivity of AXL to HSP90 Inhibitors 
A large number of HSP90 client proteins are bona fide oncoproteins. 
These include many kinases such as ERBB2, EGFR, CDK4, CRAF, BRAF, 
AKT, MET, RET and BCR/ABL, as well as transcription factors such as 
oestrogen and androgen receptors, HIF-1α and p53.  HSP90 inhibition leading 
to protein destabilization and/or degradation could be considered as a 
preliminary signature of being the client of HSP90.  To test whether AXL 
protein is downregulated upon HSP90 inhibition, we used a panel of thyroid 
carcinoma cell lines (CAL62, 8505C and TPC1) and HeLa cells, all 
endogenously expressing AXL. Cells were exposed to 17-AAG treatment in a 
dose- and time-dependent manner, and AXL protein levels were detected by 
western blotting. In all the cell lines tested, 17-AAG induced decrease of AXL 
protein levels (Fig.6A). AXL protein migrates, on Western blot, as a doublet of 
140 KDa and 120 KDa. Interestingly, we observed that 17-AAG induced a 
strong reduction of the slow-migrating 140 KDa isoform of the receptor, while 
it caused an accumulation of the 120 KDa band.  The same effect was observed 
on AXL using another HSP90 inhibitor, Radicicol, which is structurally 
unrelated to 17-AAG (Fig.6B). This effect was specific to AXL as 17-AAG 
induced degradation of other known HSP90 clients like c-KIT, RET and 
PDGFR affected equally both the mature and the immature receptor isoforms 
(Fig.6C). 
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Figure 6: (A) Protein lysates from the indicated thyroid carcinoma cell lines (CAL62, 8505C, 
TPC1) and Hela cells subjected to vehicle (0) or 17-AAG treatment in the indicated doses for 8 
hrs (upper panel) and in the fixed dose (500 nM) for indicated time course (lower panel) were 
immunoblotted using anti-AXL antibodies that recognize both the 140 KDa and the 120 KDa 
AXL isoforms. Anti-Tubulin antibodies were used as a loading control. (B) CAL62 cells 
expressing endogenous AXL were treated with the indicated concentrations of Radicicol and 
17-AAG for 8 hrs.  Equivalent amount of protein lysates were subjected to western blotting 
with anti-AXL and anti-Tubulin antibodies. (C) HeLa cells transfected with the expression 
constructs of AXL, c-KIT, RET and PDGFR were treated with 17-AAG (500nM) and 
harvested at the indicated time points were subjected to SDS PAGE and immunoblotted against 
the respective protein and Tubulin. 
 
4.1.2 17-AAG targets the completely matured AXL receptor 
 
AXL is expected to be glycosylated as its resolving pattern in SDS 
PAGE shows two bands (140 KDa and 120 KDa), in which the 17-AAG 
sensitive species of AXL was observed to be the 140 KDa isoform.  First, to 
analyse whether these two bands are glycoslylated, we treated CAL62 cells 
with the glycosylation inhibitor Tunicamycin.  As shown in figure 7A the 
tunicamycin treatment completely abrogated AXL glycosylation and hence the 
non-glycosylated isoform of AXL (100 KDa) is the only detected by SDS 
PAGE/western blotting.  This clearly infers that the two AXL isoforms (120 
and 140 KDa) are differentially glycosylated forms of the receptor.  Second, 
we proceeded to characterize the band that was sensitive to 17-AAG; to this 
aim we treated CAL62 cell lysates with two different endoglycosidases, Endo-
H and PNGase.  These glycosydases are generally used to dissect out the 
glycosylation status of a glyco-protein. In fact, PNGase removes the whole of 
N-glycans, whereas EndoH removes only the glycans of high mannose type. 
The experiment shown in figure 7B clearly depicted the glycosylation pattern 
of AXL, and confirmed that the band that was sensitive to EndoH was the high 
mannose type ie., 120KDa isoform; the band that was insensitive to EndoH, 
but sensitive to PNGase was the completely glycosylated or fully matured 
isoform (140 KDa). Thus, this experiment clarified that the AXL isoform that 
was affected by 17-AAG corresponded to the fully glycosylated and 
completely matured isoform, which is normally localized at the plasma 
membrane. 
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Figure7: (A) Lysates of CAL62 cells treated 18 hrs with the indicated doses Tunicamycin 
were immunoblotted with AXL antibodies and normalised with Anti-Tubulin. (B) 50 µg 
protein lysates of CAL62 cells  pre-boiled for 5 minutes at 99˚C and subjected to overnight 
EndoH (0.01 U) and PNGase (1 U) digestion at 37 ºC.   The lysates were run on SDS-PAGE 
and immunoblotted for anti-AXL and -Tubulin. 
 
To confirm that 17-AAG induced a decrease of the AXL isoform 
exposed on the cell surface, we performed in vivo biotin-labelling of the cell 
surface proteins in CAL62 cells treated or not with 17-AAG.  Biotinylated 
proteins were recovered with streptavidin-agarose resin and subsequently 
immunoblotted with anti-AXL antibodies. As shown in figure 8A, the 140 KDa 
AXL isoform was the only biotinylated product, indicating it normally 
localizes mainly to the cell surface. No AXL biotinylated product was detected 
in 17-AAG-treated cells, suggesting that this drug targeted the mature receptor 
thereby reducing its localization on the plasma membrane. Consistently, 
immunofluorescence staining on non-permeabilized CAL62 cells treated or not 
with 17-AAG using an anti-AXL antibody directed to AXL extracellular 
domain confirmed that 17-AAG treatment induced a strong reduction of 
surface localized AXL (Fig.8B). 
 
 
Figure 8: (A) CAL62 cells were surface labelled with biotin and treated or not with 17-AAG 
(500 nM) for 8 hours. Cells were then lysed and 1 mg of lysate was immunoprecipitated using 
streptavidin-sepharose and immunoblotted for AXL. (B) CAL62 cells, grown on coverslip, 
were subjected to vehicle (0) or 17-AAG (500 nM) treatment for 8 hrs. Cells were then fixed 
and stained for immunofluorescence using anti-AXL antibody targeting extracellular domain 
and a fluorescently labeled secondary antibody to goat immunoglobulins.  The slides were 
analysed under confocal microscope. Representative microscopy images of both treated and 
untreated cells are presented. 
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4.1.3 Functional interaction of AXL with the chaperone machinery 
components 
 
We performed co-immunoprecipitation experiments to examine the 
association between AXL and HSP90 and the crucial components of the 
chaperone complex in the presence and absence of 17-AAG.  HSP90 was co-
immunoprecipitated with AXL under basal conditions (Fig.9A). Upon 17-AAG 
treatment, AXL-HSP90 interaction initially increased but then became 
undetectable. On the contrary, HSP70 co-immunoprecipitation with AXL was 
not detectable under basal condition (Fig.9A).  However, the exposure of HeLa 
cells to 17-AAG, besides increasing the cellular concentration of HSP70, also 
promoted its interaction with AXL; these kinetics of association/dissociation of 
the chaperones suggest a shift in the chaperoning balance from folding 
(HSP90) to degradation mode (HSP70) due to the 17-AAG-dependent block of 
HSP90 activity (Kundrat and Regan 2010).   
To validate these interactions and to evaluate HSP90 interaction with 
the different AXL isoforms, we performed coimmunoprecipitation experiments 
by co-expressing AXL-Flag and HSP90-HA in HeLa cells. As shown in figure 
9B, HSP90 interacted with the high mannose AXL isoform (120 KDa) and the 
AXL core polypeptide (100 KDa), but not significantly with the fully mature 
receptor (140 KDa) under basal condition (Fig.9B), despite this particular 
isoform seemed the most affected upon 17-AAG exposure. This indicated that 
the exclusive sensitivity of AXL 140 KDa isoform towards HSP90 inhibition 
could not be explained by the selective interaction with the chaperone.  The 
HSP70-containing chaperone complex destabilizes misfolded proteins by 
recruiting many different ubiquitin ligases, among which the ubiquitin E3-
ligase CHIP was well described (Meacham et al. 2001; Murata et al. 2001). 
CHIP E3-ligase interacts with HSP70/90 via its amino-terminal 
tetratricopeptide repeat (TPR) domain (Xu et al. 2002). To test the involvement 
of CHIP in 17-AAG induced AXL ubiquitination, we co-expressed CHIP-myc 
and AXL-Flag in HeLa and assessed the co-immunoprecipitation of AXL-Flag 
in the CHIP-myc immunoprecipitate in the absence and presence of 17-AAG. 
As shown in Figure 9C, although AXL poorly interacted with CHIP under 
normal conditions, it robustly associated to CHIP upon 4 hrs of 17-AAG 
treatment, strongly indicating its functional role in mediating 17-AAG-
dependent ubiquitination of the receptor.  Surprisingly, the CHIP 
immunocomplex also displayed a predominant association with the 120 KDa 
partially glycosylated isoform and with the core polypeptide (100 KDa), with 
respect to the 140 KDa isoform. 
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Figure 9: (A) HeLa cells treated with 500 nM of 17-AAG for the indicated times were lysed 
and equal amounts of protein lysate were immunoprecipitated using the anti-AXL antibodies 
followed by immunoblotting with anti- HSP90 and   -HSP70.   AXL, HSP90 and HSP70 total 
levels were monitored using appropriate antibodies in Western blot analysis.  Tubulin 
immunoblotting was used as a loading control. (B) HeLa cells transiently co-transfected with 
AXL-Flag and HSP90-HA tagged vectors were treated with vehicle (-) or with 500 nM 17-
AAG for the indicated times. Equal amounts of protein lysate were immunoprecipitated using 
the anti-HA antibodies followed by immunoblotting with anti-Flag antibodies. AXL-Flag and 
HSP90-HA total levels were monitored using the corresponding antibodies in Western blot 
analysis. NT: non-transfected cells. Arrows indicate the 100, 120 and 140 KDa isoforms of the 
receptor. (C) HeLa cells co-transfected with AXL-Flag and CHIP-myc were treated or not (-) 
with 500 nM 17-AAG for the indicated times.  Comparable protein aliquots were 
immunoprecipitated using anti-myc antibody followed by immunoblotting with anti-Flag.  
AXL-Flag and CHIP-myc total levels were monitored using the anti-TAG antibodies in 
Western blot. NT indicates non-transfected cells. 
 
4.1.4 Results Summary Part I 
? The functional blockade of HSP90 by 17-AAG induces AXL receptor 
tyrosine kinase degradation. 
? The fully glycosylated 140KDa AXL isoform is specifically affected by 
HSP90 inhibition. 
? AXL interacts with HSP90 under normal condition and with HSP70 
and CHIP E3 ligase upon HSP90 inhibition. 
? These observations indicate AXL dependency on HSP90 chaperoning, 
suggesting AXL as a bona fide HSP90 client.  
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4.2 PART II – Molecular mechanism of 17-AAG induced AXL 
degradation 
 
4.2.1 Proteasomal inhibitors rescue 17-AAG induced AXL Loss 
 
 Nearly all proteins in mammalian cells are continually degraded either 
through the proteasomal or lysosomal machinery and are replaced by de novo 
synthesis.  Degradation may also occur as an attempt to eliminate misfolded, 
damaged or abnormally conformed proteins to counter their accumulation into 
the cells. Our data clearly demonstrated that AXL is dependent on HSP90 and 
is degraded presumably due to the induction of misfolding upon HSP90 
inhibition; we then assessed the degradation pathway involved in this process.  
To this aim we used proteasomal inhibitors Lactacystin, MG-132 and the 
Lysosomal inhibitors Chloroquine or Ammonium chloride along with 17-AAG 
in CAL62 and HeLa cell lines.   Pre-treatment of HeLa and CAL62 cells with 
proteasomal inhibitors rescued 140 KDa AXL isoform that was depleted upon 
17-AAG exposure (Fig.10). Conversely, when cells were treated with 
lysosomal inhibitors, 17-AAG retained its effect on AXL, indicating that the 
reduced levels of AXL protein induced by 17-AAG were mediated by 
proteasomal but not lysosomal degradation machinery.   
 
 
  
Figure 10: Lysates of CAL62 and HeLa cells pre-treated for 1 hr with the proteasomal 
inhibitors MG132 (10 µM) or lactacystin (5 µM), and the lysosomal inhibitors NH4Cl (20 
mM) or chloroquine (100 µM) were treated with vehichle (NT) or with 500 nM of 17-AAG for 
an additional 3 hrs and immunoblotted for AXL; Tubulin immunoblotting was used as a 
loading control.  
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4.2.2 17-AAG induced AXL polyubiquitination is mediated by CHIP E3 
Ligase 
 
 The treatment with 17-AAG by inhibiting HSP90 function alters the 
composition of the chaperone complex and recruits E3-ubiquitin Ligase, 
thereby targeting client protein to proteasome for degradation. Proteasomal 
targeting is often mediated by protein polyubiquitination. To document if AXL 
undergoes polyubiquitation upon 17-AAG treatment, HeLa cells were 
transfected with HA-tagged Ubiquitin (ub-HA) and treated with 17-AAG.  
AXL immunocomplex displayed a time dependent increase in total 
ubiquitination upon 17-AAG exposure (Fig.11A) with a peak between 2 to 3 
hrs of 17-AAG treatment after which ubiquitinated AXL levels decreased.  
AXL ubiquitination peak preceded the loss of AXL protein at later time points, 
as shown by the anti-AXL immunoblot.  AXL polyubiquitination upon 17-
AAG treatment was also verified by immunoprecipitating Ubiquitin (HA) and 
probing for AXL (data not shown).  The treatment with 17-AAG induced 
progressive accumulation of polyubiquitinated AXL species over time was also 
confirmed employing Nickel pull-down of His/myc-tagged AXL under 
denaturing condition; HeLa cells were cotransfected with Ub-HA and His/myc 
AXL, and purified AXL by Nickel pull down was probed for HA (ub) to 
evaluate its ubiquitination level (Fig.11B).  Since the nickel pull-down was 
performed under denaturing conditions, this experiment allowed us to exclude 
that the polyubiquitinated protein observed was AXL itself and not an 
associated protein pulled down by the AXL immunocomplex, reinforcing that 
17-AAG induced AXL-polyubiquitination and targeted it to proteasome 
degradation machinery. 
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Figure 11: (A) HeLa cells, transiently transfected with HA-tagged ubiquitin (ub-HA), were 
subjected to vehicle (NT) or to 500 nM 17-AAG treatment 48 hrs post-transfection and were 
harvested at the indicated time points.  Upon cells lysis, equal amounts of proteins were 
immunoprecipitated using anti-AXL antibodies and immunoblotted with antibodies against the 
HA epitope.  AXL immunoblotting is also shown.  (B)HeLa cells co-transfected with ub-HA 
and His tagged AXL (sub-cloned in pCDNA 4 TO A His/myc) were treated or not with 500 
nM of 17-AAG for the indicated times.  Cells were harvested and comparable amounts of cell 
suspension were subjected to His-tag (AXL) protein purification under denaturing conditions 
following the protocol mentioned in the materials and methods section. Nickel affinity purified 
proteins were resuspended in sample buffer and blotted with anti-HA for Ubiquitin and anti-
myc for AXL. 
 
To validate the involvement of CHIP in 17-AAG induced AXL 
polyubiquitination, we exogenously expressed wt CHIP together with ub-HA 
in HeLa cells. By immunoprecipitating AXL and probing for HA (ub), we 
observed an increased AXL polyubiquitination in CHIP wt overexpressing 
cells. AXL ubiquitination increased in the presence of 17-AAG and was further 
enhanced by lactacystin treatment, which rescued polyubiquitinated protein 
from proteasomal degradation (Fig.12A). We also used the CHIP K30A (Xu et 
al. 2002; Alfano et al. 2010), a mutant in the CHIP TPR domain that acts as a 
dominant negative mutant since it does not interact with the chaperone 
complex.  When CHIP K30A was ectopically co-expressed with ub-HA in 
HeLa cells, it was able to abrogate 17-AAG induced AXL polyubiquitination 
acting in a dominant negative fashion on endogenous CHIP E3 Ligase (Fig. 
12A). These data clearly demonstrated the role of endogenous CHIP E3 ligase 
in 17-AAG induced AXL polyubiquitination (Zhou et al. 2003; Morishima et 
al. 2008).  As expected CHIP wt but not CHIP K30A was capable of 
interacting with AXL (Fig.12B). 
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 Figure 12: (A) HeLa cells co-transfected with Ub-HA and CHIP wt or CHIP K30A was 
treated with 500 nM 17-AAG (3 hrs) with and without Lactacystin (10 µM) pre-treatment.  
Cells were lysed and equal amount of proteins were immunoprecipitated using anti-AXL 
antibodies and immunoblotted with anti-HA antibodies.  Anti-AXL immunoblotting was 
performed to monitor AXL levels upon different treatments and anti-myc immunoblotting to 
check CHIP expression. Tubulin immunoblotting was used as a loading control. NT: non-
transfected cells (B) HeLa cells co-transfected with Flag-tagged AXL (AXL) and myc-tagged 
CHIP wild type (CHIP wt) or the mutant CHIP K30A, and treated with 500 nM 17-AAG were 
subjected to immunoprecipitation using anti-myc antibody; CHIP immunocomplexes were 
probed for anti-Flag antibodies.  Anti-Flag and anti-myc immunoblotting of total cell lysates 
was used to check AXL and CHIP levels, respectively. 
 
 
4.2.3 Effect of 17-AAG on the plasma membrane localized AXL 
 
As we observed that 17-AAG specifically depleted AXL species that 
was localized on cell surface, we asked whether 17-AAG induced AXL loss 
was due to a direct effect on the plasma membrane associated receptor.  
Experimentally, we tested this by biotin pulse-labelling the surface protein in 
CAL62 cells and subsequently chasing until 6 hrs in the presence of vehicle or 
17-AAG.  Extracts were pulled-down using streptavidin-conjugated beads to 
isolate biotin labeled proteins, separated on SDS PAGE and probed for AXL. 
The outcome of this experiment showed that 17-AAG marginally affected the 
quantity of surface-bound receptor with respect to vehicle treated cells only at 
the later time points (Fig.13A), while it strongly affected at its steady state 
levels at 4-6 hrs of chase, indicating that 17-AAG neither affected the 
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stabilization of membrane resident receptor nor it accelerated the membrane-
localized AXL turnover.   
     
 
Figure 13: CAL62 cells were subjected to 30 min biotinylation of surface proteins and then 
chased for the indicated times with complete media in the presence or in the absence of 17-
AAG (500 nM). Biotinylated proteins were pulled-down using streptavidin-conjugated beads, 
and the complexes were probed for anti-AXL antibodies on the Western blot.  Anti-AXL 
immunoblotting of total cell lysates was used to check total AXL levels. 
 
 To validate the finding that 17-AAG doesn’t affect the pre-existing 
plasma membrane localized AXL receptor, we performed another surface 
biotin labelling experiment in order to monitor the  pre-existing plasma 
membrane localized AXL isoform (140 KDa) and its fate upon treatment with 
MG132, 17-AAG or their combination for 5 hrs. This was achieved by 
biotinylating surface proteins before treatment.  Lysates were subjected to 
Streptavidin agarose pulldown, SDS PAGE and western blotting.  As shown in 
figure 14, MG132 by itself stabilized the pre-existing membrane receptor 
species, comparing to this no significant improvement of AXL levels were 
observed when cells were co-treated with 17-AAG and MG132.  As expected, 
17-AAG treatment did not significantly affect the pre-existing receptor at the 
membrane. 
 The same experiment was also performed by biotinylating surface 
proteins post-treatment and assessing the prevalence of the surface resident 
AXL, which corresponds to the receptor that is newly synthesized and reached 
the surface during the treatment course of 5hrs.  This revealed that MG132 
treatment reduced prevalence of surface receptor in comparison with non-
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treated; 17-AAG reduced AXL surface levels and this effect was reverted by 
MG132 (Fig.14). 
 These two observations suggested that 17-AAG doesn’t affect the 
surface localized AXL receptor.  In contrast, 17-AAG strongly inhibits the 
delivery of newly synthesized AXL on plasma membrane.  Interestingly, 
MG132 could rescue membrane localised AXL, probably by either blocking 
AXL proteasomal degradation and/or increasing the half-life of membrane 
bound receptors as shown in figure 14. 
 
  
    
Figure 14.  CAL62 cells biotinylated before and after treatments with 17-AAG (500nM), 
MG132 (10µM), and 17-AAG+MG132 for 5hrs, were subjected to streptavidin 
immunoprecipitation and the recovered biotinylated proteins bound streptavidin agarose beads 
were denatured, SDS PAGE and western blotting by probing against AXL on the IP 
streptavidin blots.  5% of the total volume of lysates subjected to immunoprecipitation was 
used as total lysates for normalization. 
 
4.2.4 HSP90 inhibition blocked AXL transport to the cell surface  
 
 Having demonstrated that 17-AAG doesn’t affect the surface localized 
species of AXL, we aimed to identify whether HSP90 inhibition affects AXL 
protein biogenesis/trafficking.  To this aim, we metabolically labelled CAL62 
cells with [35S] cysteine-methionine for 15 min and chased with non-
radioactive medium for periods up to 4 hrs in the presence or in the absence of 
17-AAG (Fig. 15).  In untreated CAL62 cells, AXL completed its glycosylation 
within 60 min as indicated by the appearance of the 140 KDa isoform.  Both 
140 and 120 KDa isoforms progressively accumulated, and at 4 hrs of chase, 
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the 140 KDa AXL isoform is the prevalent one. By contrast, when CAL62 cells 
were treated with 17-AAG, only the 120 KDa isoform accumulated, and a 
complete lack of the fully glycosylated receptor was observed. These data 
suggested that 17-AAG-induced AXL downregulation occurs before reaching 
the cell surface, and that the drug either impairs maturation of the 120 KDa to 
140 KDa AXL isoform and/or induces degradation of 140 KDa isoform in the 
intracellular component.  In either case, 17-AAG blocks the delivery of fully 
glycosylated AXL protein to cell surface. 
                
Figure 15: CAL62 cells grown in complete medium were exposed to cysteine-methionine-free 
DMEM containing dialyzed 2% FBS for 1 hr.   Cells were then pulsed with 35S 
methionine/cysteine for 15 minutes and chased with nonradioactive medium for the indicated 
times with or without 17-AAG (500 nM).  At each time point, cells were lysed and subjected to 
immunoprecipitation with anti-AXL antibodies, SDS PAGE and Gel dried was exposed to 
radioactivity. 
 
4.2.5 Kinase domain but not the kinase activity sensitises AXL to 17-AAG 
 
To localize the region that sensitizes AXL to 17-AAG, we used the 
AXL-EC mutant that lacks the entire intracellular domain and has only the 
extracellular and transmembrane domain.  As a control we used a similar 
construct of the HER2 receptor (HER2-EC), because HER2 is a well 
established HSP90 client.  It has been shown that HER2 sensitivity to 17-AAG 
requires its kinase domain.  Moreover, both the immature and completely 
glycosylated isoforms of HER2 are equally sensitive to 17-AAG, differently 
from what we observed in AXL.  In addition to the extracellular alone mutants 
we also used AXL/HER2, which is a chimera of AXL extracellular domain 
fused to HER2 tyrosine kinase domain, and the reverse chimera where the 
tyrosine kinase domain of AXL is fused to extracellular domain of HER2 ie., 
HER2/AXL.  We transiently transfected these constructs in HeLa cells and 
tested their sensitivity to 17-AAG.  The result showed that the AXL-EC and 
HER2-EC are insensitive to 17-AAG (Fig.16B), depicting that similar to HER2 
it is the kinase domain of AXL that offers sensitivity to 17-AAG.  In addition 
to the EC mutants, we also used AXL/HER2, which is a chimera of AXL 
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extracellular domain fused to HER2 tyrosine kinase domain, and the reverse 
chimera where the tyrosine kinase domain of AXL is fused to extracellular 
domain of HER2 ie., HER2/AXL.  As shown in Figure 16B, 17-AAG 
sensitivity was retained when the two kinase domain were swopped between 
the two receptors. 
 
                                                                   
                        
Figure 16: (A) Schematic representation of AXL wt, HER2 wt, AXL-EC, HER2-EC, 
AXL/HER2 and HER2/AXL  (EC-Extracellular domain, TM-Transmembrane domain, shaded 
portion-Tyrosine kinase domain).   (B) HeLa cells were transiently transfected with wild type, 
EC  mutants and chimeric constructs of AXL and HER2 expression vectors and treated with 
500 nM 17-AAG (+) or vehicle (-) for 8 hrs and the lysates were immunoblotted with anti-
Flag/myc.  Tubulin immunoblotting was used as a loading control. 
 
 
Having shown that the kinase domain of AXL confers sensitivity to 17-
AAG, we then asked whether the kinase activity is also required.  To this aim, 
we used CAL62 cells that presents phosphorylated AXL due to intrinsic 
presents of its ligand Gas6 (Avilla et al. 2011).  We also found, Bosutinib that 
is reported to abrogate AXL phosphorylation (Asish et al., 2011) do interfered 
with AXL kinase activity in this system.  We then tested Bosutinib pre-treated 
CAL62 cells for 17-AAG induced degradation of AXL. This experiment 
revealed no change in the degradation kinetics between 17-AAG treated and 
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17-AAG and bosutinib co-treated cells (Fig.17A).  Consistent with this, the 
AXL kinase dead mutant (AXL K558R) overexpressed in HeLa cells retained 
its sensitivity to 17-AAG confirming that the kinase activity is not necessary 
for 17-AAG induced AXL degradation (Fig.17B).  
 
            
Figure 17:  (A) CAL62 cells pretreated with Bosutinib (5µM) were co-treated or not with 17-
AAG, harvested at the indicated time points and lysates were subjected to western Blotting. 
Anti-AXL, anti-phospho AXL and Tubulin were probed to assess the degradation kinetics, 
phosphorylation status and normalization respectively. (B) HeLa cells transfected with AXL 
WT and AXL KD were assessed for its 17-AAG sensitivity by treating them with 500 nM 17-
AAG and harvested on time course. The lysates were subjected to western blotting and probed 
against their respective tag.  Tubulin immunoblot was performed for normalization. 
 
4.2.6 Results Summary Part II 
? The proteasomal inhibitors MG132 and Lactacystin recovered the 17-
AAG induced AXL loss of 140 KDa AXL isoform suggesting the 
involvement of proteasomal machinery in this process. 
? The intervention of proteasomal machinery is confirmed as AXL 
displayed a progressive accumulation of its polyubiquitinated species 
upon 17-AAG preceding receptor degradation. 
? Like most other HSP90 clients, it is the CHIP E3 ligase that mediates 
AXL polyubiquitination upon induction of its misfolding by HSP90 
inhibition. 
? In contrast to other HSP90 clients, the specific effect of 17-AAG on 
AXL 140 KDa isoform is probably due to the degradation of trafficking 
AXL in the cytosol, rather than directly targeting the membrane 
localised fully glycosylated AXL on the plasma membrane. 
? It is the AXL Kinase domain that confers sensitivity of this receptor to 
17-AAG. 
? The kinase activity of the receptor doesn’t play a role in 17-AAG 
sensitivity. 
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4.3 PART III – The effect of 17-AAG on AXL driven signalling and 
biological activity 
4.3.1 17-AAG targeting AXL interferes with its signalling and biological 
activity 
 
 Having demonstrated the effect of HSP90 inhibition over AXL, we then 
intend to address the impact of 17-AAG on AXL-driven signalling and 
biological activity.  To this aim, we used two different ATC cell lines: CAL62 
and 8505C, previously characterized for their dependence on AXL signalling 
in acquiring survival advantage.  As expected 17-AAG exposure of these cells 
induced a reduced AXL phosphorylation concomitant with its decreased total 
protein.  In addition, upon 17-AAG treatment we observed the reduced 
activation of AKT and p70-S6 kinase (Fig.18A) upon 17-AAG, which are the 
predicted AXL downstream substrates in these models (Avilla et al. 2011). As 
a control, we could show similar effects over AXL phosphorylation and 
signaling using the AXL kinase inhibitor Bosutinib.  Moreover, as a readout of 
AXL-induced biological activity, we used an AP-1 dependent Luc vector.  The 
transfection of the AP1 Luc vector in HeLa cells did not result in significant 
Luc activity.  Instead, AXL co-expression induced a strong activation of AP-1 
dependent promoter activity.  Such activity was inhibited by 17-AAG in a 
dose-dependent fashion, with a reduction of approximately 50% at 100 nM, 
and complete inhibition of promoter activation at 200 nM (Fig.18B).  This data 
indicated that 17-AAG exposure was able to selectively interfere with AXL 
mediated biological activity. 
 
 
  
Figure 18: (A) CAL62 and 8505C cells treated with 17-AAG and Bosutinib in varying doses 
were subjected to western blotting.  The signalling substrates of AXL in these models like 
p70S6 Kinase and AKT was probed with the respective phospho and total antibodies. Tubulin 
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immunoblotting was used as a loading control.  (B) HeLa cells were transiently transfected 
with AXL-Flag expressing vector and the AP1-Luc vector. pRL-null (a plasmid expressing the 
enzyme Renilla luciferase from Renilla reniformis) was used as an internal control. Firefly and 
Renilla luciferase activities are expressed as percentage of residual activity of 17-AAG treated 
cells with respect to untreated cells. Average results of three independent assays ± S.D. are 
indicated. The ANOVA Bonferroni multiple comparison test was used to demonstrate 
statistical significance. 
 
4.3.2 Results Summary Part III   
? 17-AAG induced AXL loss resulted in a reduced AXL phosphorylation 
and signalling. 
? The HSP90 inhibition selectively interfered with AXL mediated 
biological activity. 
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4. DISCUSSION 
XL overexpression and activation has been implicated in the 
progression of several human cancers and in mediating drug resistance.  In 
addition, we recently reported the overexpression and activation of AXL in 
thyroid carcinoma.  We demonstrated the crucial role of AXL in sustaining 
proliferation, survival, motility and invasiveness in driving thyroid carcinoma, 
supporting the notion that AXL could be oncogenic when overexpressed and 
hyperactive.  Despite the number of evidences showing the oncogenicity of 
AXL, the advent of specific and clinically relevant antagonists like antibodies 
or tyrosine kinase inhibitors against AXL remained elusive.  These antagonistic 
approaches against AXL continued to be challenging due to the lack of 
evidence illustrating the regulation of AXL over-expression and its innate 
capability to avail activation through diverse modes.  For instance, AXL can be 
activated by (i) ligand dependent dimerization, (ii) ligand independent 
dimerization, (iii) heteromeric dimerization with the other TAM family 
receptors, (iv) heterotypic dimerization with a non-TAM Family receptor, and 
(v) trans-cellular binding of extracellular domains (Hafizi et al. 2006 & Linger 
t al. 2011).  According to published preclinical reports the kinase inhibitors 
MP470, SKI-606 (Bosutinib) and R428 showed inhibitory effect on AXL 
ignalling along with other targets. In addition, a phage-derived mAb 
th human and murine AXL (Ye et al. 2010) 
 effect on Gas6 mediated AXL signalling. However, the 
specific
A
e
s
(YW327.6S2) that recognizes bo
displayed antagonistic
ity and the convincing effect of these agents against the complex AXL 
signalling at the clinical setting still represent major concerns that have not yet 
been addressed.   
We attempted to provide evidence that AXL could be effectively 
targeted employing a clinically relevant HSP90 inhibitor, Ansamycin antibiotic 
Geldanamycin analog 17-AAG.  The usage of Ansamycin antibiotics to 
downregulate RTKs represents a promising tool in deactivating HSP90 
dependent oncogenic signal transducers.   Based on the unique and 
therapeutically attractive effect of HSP90 in regulating multiple tumor survival 
and progression pathways, extensive studies in developing HSP90 inhibitors 
are being performed, and the number of inhibitors is rapidly increasing.  More 
importantly, studies have shown that 17-AAG binds to HSP90 in cancer cells 
with about 100-fold higher affinity than it does in normal cells (Kamal et al. 
2003). The difference might come from the different states of HSP90 in cancer 
cells and normal cells because the tumor HSP90 is mostly in multi-protein 
complexes with high ATPase activity, probably due to the increased load of 
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mutant client proteins (Kamal et al. 2003); whereas, HSP90 from normal cells 
are mainly in an uncomplexed state that has low ATPase activity (Kamal et al. 
2003).  
 HSP90 and its related co-chaperones play a regulatory role in 
maintaining conformational maturation and structural integrity of a variety of 
cellular proteins.  In this study we show that AXL is dependent on HSP90 for 
its maturation and continued transport to the plasma membrane.  Employing 
17-AAG, we observed that AXL is degraded in a panel of thyroid carcinoma 
cell lin
ation in the multichaperone complex but also indicates the fate of AXL 
tein
er, the possible involvement of 
other E3 ligases in 17-AAG induced protein degradation of HSP90 clients 
es as well as in HeLa cells.  This effect was reproduced when a 
chemically unrelated drug, Radicicol was used to inhibit HSP90.  Interestingly, 
AXL degradation resulting from 17-AAG affected disproportionately the 
completely glycosylated receptor (140 KDa), rather than the newly synthesized 
(100 KDa) or the partially glycosylated AXL species (120 KDa).  Hence, the 
exposure to 17-AAG reduced the prevalence of AXL receptor on the plasma 
membrane.  This specific effect of depleting only the fully matured receptor 
was observed for AXL but not in other HSP90 clients c-KIT, RET and PDGFR 
that are sensitive at all stages of maturation.  
 The effect of 17-AAG on AXL protein was clearly shown to have 
functional relevance to HSP90 inhibition, as we could show the interaction 
between HSP90 and AXL under normal conditions; and it was curtained upon 
17-AAG exposure on time.  Besides this, the AXL immunocomplex displayed 
an increasing association to HSP70 on time with 17-AAG.  This shift in the 
associating partners of chaperone complex with AXL, not only demonstrates 
the alter
pro  within the complex.  The shift from the normal folding mode to the 
degradation mode of chaperone complex, mediates CHIP E3 ligase recruitment 
and links the chaperone associated client to proteasome degradation machinery 
(Kundrat and and Regan 2010). 
CHIP E3 ligase recruitment in the AXL associated chaperone complex 
observed only upon HSP90 inhibition. The ability of wt CHIP, but not of CHIP 
TPR mutant (CHIP K30A), to ubiquitinate AXL supports the involvement of 
CHIP E3 ligase in AXL-polyubiquitination at least in the context of HSP90 
inhibition.  Though CHIP K30A was capable of abolishing AXL ubiquitination, 
it could not completely stop the loss of AXL induced by 17-AAG.  These data 
were also confirmed by RNA interference of CHIP in HeLa and CAL62 cells 
(data not shown). We cannot exclude that our approaches could not achieve a 
complete inhibition of CHIP function, and the residual activity might be still 
sufficient to degrade client proteins. Howev
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should be considered as well. By using CHIP-/- mouse embryo fibroblasts, it 
has been shown that CHIP role in ubiquitination and turnover of HSP90 client 
proteins is not exclusive and that other E3 ligases may complement CHIP 
deficiency (Xu et al. 2002; Morishima et al. 2008).  Moreover, our data also 
suggest the possibility of an alternate pathway that guides the clearance of the 
misfolded proteins.  
Though the concept of client RTK destabilization upon HSP90 
inhibition came into light decades ago, this is the first report dissecting the 
HSP90 inhibitory effect on differentially glycosylated species of a client 
protein.   The molecular explanation behind this differential effect was obtained 
by analysing the steady-state AXL levels and surface receptor turnover, by 
assessi
AXL remained unaffected, at least until 4hrs of chase 
points i
 KDa recovery observed in western blotting 
analysi
ng the MG132 rescued AXL species from 17-AAG induced degradation 
and by tracking the newly synthesized and the trafficking AXL in the presence 
and in the absence of 17-AAG.  
Our analysis on steady state level showed that AXL loss induced by 17-
AAG is at the plasma membrane, and the proteasomal inhibitor MG132 did 
rescue this 17-AAG induced effect.  Despite, neither HSP90 nor CHIP E3 
ligase immunocomplexes showed a predominant association with the 
membrane associated 140 KDa AXL species but interaction observed 
significantly with 120 and 100 KDa AXL isoforms.  This insignificant 
association of 140 KDa species to HSP90/CHIP is due to the phosphorylation 
gained in that isoform rendering the interaction more fragile and hence 
detection was improbable; this we confirmed using the AXL kinase dead 
mutant that displayed a predominant association of its 140KDa isoform 
likewise 120 and 100 KDa isoform to HSP90/CHIP immunocomplexes (data 
not shown).  The surface protein biotin labelling to assess the turn-over of  
membrane localized AXL showed that the destiny of the pre-existing 
membrane localized 
n the presence of 17-AAG. 
Surface protein biotin labelling followed by MG132 treatment alone or 
in combination with 17-AAG aided to monitor the fate of the pre-existing 
membrane localized AXL along with the identity of the rescued species by 
MG132.  This experiment showed that MG132 stabilized the pre-existing 
surface localized receptor, while 17-AAG did not affect AXL levels.  The 
specific effect of MG132 in stabilizing the surface localized AXL isoform 
could partially explain AXL 140
s of total proteins under co-treatment conditions (Fig.14B), however, we 
cannot exclude that part of this MG132 recovery is also be due to the rescued 
species from 17-AAG effect, since on total lysates MG132 barely increases 
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AXL levels compared to non-treated but does a significant recovery on co-
treatment with 17-AAG.  The fate of newly synthesized membrane localized 
AXL in the presence of 17-AAG and MG132 has been assessed by biotin 
labelling after treatments with the two compounds.  MG132 reduced AXL 
prevalence on cell surface, and this probably due to overload of secretary 
pathway with polyubiquitinated proteins.  17-AAG treatment strongly reduced 
AXL appearance on the cell surface, and MG132 co-treatment reverted this 
effect.  However, this reversion might include the stabilized pre-existing 
surface resident AXL as well as the recovered AXL transport to the cell 
membrane that bypassed the 17-AAG effect.  Whatever the case, our data 
clearly emphasized that 17-AAG does not affect plasma membrane localized 
AXL.  Furthermore, by exploiting 35S methionine pulse-chase experiment, we 
observe
of many different types of cancer and there is enough evidence to support its 
d no 140 KDa species in the presence of 17-AAG, by contrast, in 
untreated cells AXL accumulated first as 120 KDa isoform and then as a 140 
KDa species that represents the mature membrane exposed receptor. This 
observation suggests 17-AAG depletes the completely matured AXL species by 
blocking its maturation and degrading the receptor at the cytosol before having 
reached the membrane. 
Other HSP90 client proteins, such as the HER2, RET, PDGF or c-KIT 
receptor tyrosine-kinases require chaperone activity for the correct folding and 
stability of both mature and immature forms. In contrast to HER2, the TrkAI 
receptor is similar to AXL, because it requires HSP90 for its maturation and 
cell surface translocation. In fact, 17-AAG treatment of TrkAI expressing cells 
causes the degradation of the fully mature receptor and the accumulation of the 
immature one (Farina et al. 2009).   
Our data also showed that an AXL receptor carrying an intact tyrosine 
kinase domain retained sensitivity to 17-AAG, while the AXL-EC, an ICD 
deletion mutant completely lost the response. Moreover, when the tyrosine 
kinase domains of AXL and HER2 were swopped between each other, both the 
chimeric constructs retained the sensitivity to 17-AAG, despite their ICD 
deletion mutants (AXL-EC and HER2-EC) failed to respond.  This reinforces 
the hypothesis that like HER2, it is the TK domain of AXL that is necessary to 
avail sensitivity towards HSP90 inhibitors.  Furthermore, our data proved that 
AXL kinase activity is not required for this effect.  This is in favour of the 
hypothesis that the HSP90 binding determinants are located in the kinase 
domain, and this association depends on the intrinsic structure and stability of 
the receptor TK domain (Shimamura et al. 2005; Taipale et al. 2012) rather 
than on its activity.  AXL overexpression and activation appears to be a feature 
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oncogenic activity (Li et al. 2009).  We have previously demonstrated that AXL 
is overexpressed and active in thyroid cancer. In thyroid carcinomas, AXL 
ligand,
; Zhang et al. 2012).  These documented 
evidenc
 GAS6, is also frequently expressed either by thyroid cancer cells or, in 
some cases, by stromal cells. We have shown that silencing AXL expression by 
RNA interference hampers thyroid cancer cell proliferation, survival, migration 
and tumor formation in immunodeficient mice (Avilla et al. 2011). Moreover, it 
has been reported that AXL overexpression is a frequent mechanism of 
resistance to different anticancer agents (Huang et al. 2010; Liu et al. 2009; 
Hong et al. 2008; Dufies et al. 2011
es clearly put forth the role of AXL in pathogenesis and progression of 
various human malignancies.  We have shown that 17-AAG inhibits AXL 
activation, signalling and biological activity.  However, we cannot exclude that 
such effects could likely be due to the cumulative effect of 17-AAG on several 
HSP90 client proteins, rather than AXL alone. 
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6. CONCLUSION 
The molecular chaperone HSP90 is a promising target of anti-cancer 
rugs. Many of the HSP90 “client” proteins are involved in cancer signaling 
 predicted to simultaneously affect 
ultiple oncogenic signaling pathways. Several HSP90 inhibitors, including 
17-AAG, show very high selectivity for HSP90 in tumor cells compared to 
ormal cells. 17-AAG has entered phase I/II clinical trials with very good 
are under preclinical development.  
everal preclinical and clinical reports have illustrated that chemical 
ptimization of HSP90 inhibitors with improved efficacy and selectivity might 
e effective against therapeutically complex tumors. 
Our attempt to validate and address the effects and mechanism of 17-
 AXL as a bona fide client of 
SP90 and the therapeutic approach to target HSP90 would counteract AXL 
overexpression and its aberrant activation in human malignancies along with 
e growing list of HSP90 oncogenic clients.  Besides providing evidence that 
 can be targeted via HSP90 inhibition, our data also widens the 
nderstanding of HSP90 chaperoning, its biological importance and more 
portantly the therapeutic modality of using HSP90 inhibitors as an anti-
ancer agent at least against selective or tumor addictive HSP90 clients. 
Our data convincingly demonstrated that AXL can be listed among 
timized HSP90 inhibitors, we strongly 
cted tumors or drug resistance conditions may be 
onsidered as an optimal scenario to employ HSP90 inhibitors to counteract 
XL. 
 
 
 
d
pathways. Hence, inhibition of HSP90 is
m
n
effectiveness. Many other inhibitors 
S
o
b
AAG on AXL downregulation indicates that
H
th
AXL
u
im
c
HSP90 clients.  In the advent of op
recommend AXL addi
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Therapeutics, Targets, and Chemical Biology
Activation of TYRO3/AXL Tyrosine Kinase Receptors
in Thyroid Cancer
Elvira Avilla1, Valentina Guarino1, Carla Visciano1, Federica Liotti1, Maria Svelto1,3,
GnanaPrakasam Krishnamoorthy1, Renato Franco3, and Rosa Marina Melillo1,2
Abstract
Thyroid cancer is the most common endocrine cancer, but its key oncogenic drivers remain undefined. In this
study we identified the TYRO3 and AXL receptor tyrosine kinases as transcriptional targets of the chemokine
CXCL12/SDF-1 in CXCR4-expressing thyroid cancer cells. Both receptors were constitutively expressed in
thyroid cancer cell lines but not normal thyroid cells. AXL displayed high levels of tyrosine phosphorylation in
most cancer cell lines due to constitutive expression of its ligand GAS6. In human thyroid carcinoma specimens,
but not in normal thyroid tissues, AXL and GAS6 were often coexpressed. In cell lines expressing both receptors
and ligand, blocking each receptor or ligand dramatically affected cell viability and decreased resistance to
apoptotic stimuli. Stimulation of GAS6-negative cancer cells with GAS6 increased their proliferation and
survival. Similarly, siRNA-mediated silencing of AXL inhibited cancer cell viability, invasiveness, and growth of
tumor xenografts in nude mice. Our findings suggest that a TYRO3/AXL-GAS6 autocrine circuit sustains the
malignant features of thyroid cancer cells and that targeting the circuit could offer a novel therapeutic approach
in this cancer. Cancer Res; 71(5); 1792–804. 2011 AACR.
Introduction
Thyroid cancer is the most common endocrine malignancy
and its incidence is increasing worldwide. Thyroid cancer
histotypes include: well-differentiated papillary and follicular
(PTC and FTC), poorly differentiated (PDTC) and anaplastic
thyroid carcinoma (ATC; ref. 1, 2, 3). Thyroid cancer features
overexpression of specific chemokine and their receptors
(4, 5). CXCR4/SDF-1 axis has an important role in promoting
cell growth, invasiveness, and survival in thyroid cancer cells
and its blockade can revert all these phenotypes (4, 5, 6). We
analyzed global gene expression profiles of CXCR4-expressing
human PTC cells (TPC-1) with or without SDF-1a. We iden-
tified TYRO3 and AXL, belonging to the TAM family (Tyro3,
Axl, and Mer) of tyrosine kinase receptors (7, 8). TAM-
mediated signaling is involved in cell survival, proliferation,
migration and adhesion (9), vascular smooth muscle home-
ostasis (10), platelet function (11; 12), and erythropoiesis (11).
These receptors are frequently coexpressed in vascular, repro-
ductive, nervous, and immune system in adults (13). TAM
receptors can be activated by 2 physiological ligands, GAS6
(Growth-Arrest-Specific gene 6) and Protein S, which are
homologous vitamin-K–dependent proteins (13). TAM recep-
tors are involved in cancer development and progression. AXL
overexpression is observed in many human cancer types. Gas6
is frequently expressed in cancer and its level correlates with
poor prognosis (14).
The aim of this report is to study TAM receptor involvement
in thyroid cancer. We show that human PTC/ATC cells and
samples, but not normal thyroid, constitutively express AXL,
TYRO3, and their ligand GAS6. We show that AXL, TYRO3, and
GAS6 have a critical role in mediating thyroid cancer cell
proliferation, invasiveness, and survival. Moreover, we show
that silencing of AXL in an ATC cell line strongly affects tumor
growth in immunodeficient mice. These data provide evidence
that the AXL/TYRO3/GAS6 axis might be exploited as target
for potential antitumoral therapy.
Materials and Methods
Cell cultures
Human primary cultures of normal thyroid were obtained
from F. Curcio (Dipartimento di Patologia e Medicina Sper-
imentale e Clinica, University of Udine, Italy;) and cultured as
described (15). Human thyroid papillary cancer cell lines
TPC1, BCPAP, NIM, and anaplastic thyroid cancer cell lines
850–5C, CAL62, U-HTH83, C643, SW1736, U-HTH7, U-HTH83,
C643, SW1736, OCUT-1, ACT-1 have been previously described
(15–17). PC, PC BRAF, PC HaPTC3, PC E1A, PC PTC1, PC E1A-
RAF, PC PTC3, PC v-mos, PC E1A-RAF rat thyroid epithelial
cells have been previously described (4, 5, 18). Transformed
human embryonic kidney cells (293T) have been obtained by
ATCC (19). TPC1 and NIM were obtained from Dr. M. Santoro
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(University of Naples, Naples, Italy); BCPAP, CAL62, and
850-5C were purchased from Deutsche Sammlung von Mik-
roorganismen und Zellkulturen GmbH. OCUT-1 and ACT-1
were a gift of K. Hirakawa and N. Onoda (Department of
Surgical Oncology, Osaka City University Graduate School of
Medicine, Osaka, Japan) and SW1736, C643, U-HTH7, and U-
HTH83 cells were a gift of C.H. Heldin (Ludwig Institute for
Cancer Research, Uppsala University, Uppsala, Sweden). All
cells have been tested for specific mutations and thyroid
marker expression. Cells are passaged for fewer than 3
months.
Histology and immunohistochemistry
Thyroid tissue samples from patients affected by thyroid
carcinomas and normal thyroid tissues were obtained from
the Struttura Complessa di Anatomia Patologica, Istituto
Nazionale Tumori of Naples, upon informed consent. Anti-
AXL, anti-GAS6, and anti-CXCR4 antibodies from R&D Sys-
tems were used to stain human thyroid carcinoma samples.
For xenograft hystological analysis, Ki67 antibody (Clone
MIB-1) was from Dako, and CD31 antibody was from Santa
Cruz Biotechnology; samples were processed with peroxidase
detection system reagent kit (Novocastra). Apoptosis was
evaluated by the terminal deoxynucleotidyl transferase
(TdT)-mediated dNTP-labeling (TUNEL) method using Fragel
DNA fragmentation detection kit colorimetric-TdT enzyme by
Calbiochem—Merck KgaA (Darmstadt). Four mm-thick sec-
tions were deparaffinized and rehydrated and antigen retrieve
technique was carried out in pH 6.0 buffer in amicrowave for 3
minutes using standard histological technique. Evaluation has
been done by an expert pathologist (R. Franco). For vessel
examination, the stained sections were screened at low power
(40), and 3 areas with the most intense neovascularization
(hot spots) were selected. Mean vessel lumen cross-sectional
diameter were determined for 10 hot spot 40 areas, all
counted based upon spatial calibration parameters estab-
lished with a slide digital micrometer (Olympus cellSens
digital image analysis system).
RNA interference
SMARTpools (custom-synthesized siRNA) by Dharmacon
were used for AXL, TYRO3, and GAS6 silencing. Cells were
grown under standard conditions. The day before transfec-
tion, cells were plated in 6-well dishes at the density of 3 
105. Transfection was done by using 100nmol/L of SMART-
pool and 6 mL of DharmaFECT (Dharmacon). Cells were
harvested at 24 hours after transfection and analyzed by WB
and FACS.
Generation of stable AXL shRNA- and AXL dominant-
negative expressing cell lines
We obtained 5 lentiviral constructs (pLKO.1puro) contain-
ing 21-mer short hairpin RNAs (shRNA) directed to various
coding regions of AXL (Mission shRNA, pLKO.1 puro) from
Sigma-Aldrich, Inc (20). 850–5C were electroporated with the
pool of shRNAs directed against AXL or with a pool of
nontargeting vectors (shCTR). Stable transfectants were
selected in medium with 500ng/mL puromycin. To block
AXL, we also generated 850-5C cells that stably express
dominant-negative forms of the receptor, that is FLAG-tagged
AXL EC, that lacks the whole intracellular domain, and the
kinase dead mutant of AXL carrying the mutation K558R,
which abrogates TK activity (Myc-tagged AXL KD). Detailed
experimental procedures regarding these mutants are
included in Supplementary data.
Protein studies
Protein extractions, immunoblotting, immunoprecipita-
tion, and pull-down binding assays were carried out according
to standard procedures. Anti-AXL were from Santa Cruz
Biotechnology. Anti-TYRO3 was from R&D Sysyems. Anti-
phospho AXL, specific for tyrosine 779, was from R&D Sys-
tems. Anti-phosphotyrosine antibody (4G10) was from
Upstate Biotechnology. Anti-AKT and anti-phospho-AKT
were from Cell Signaling. Anti-phospho-p44/42 MAPK and
anti-p44/42 MAPK were from Cell Signaling. Anti-phospho-
p70S6K and anti-p70S6K were from Cell Signaling. Monoclo-
nal anti-tubulin was from Sigma Chemical Co. Anti-GRB2
antibodies were from Santa Cruz Biotechnology; anti-p85
was from Cell Signaling. Secondary anti-mouse, anti-goat,
and anti-rabbit antibodies coupled to horseradish peroxidase
were from Bio-Rad. Detailed experimental procedures can be
found in Supplementary data.
ELISA assay
Thyroid cells were allowed to grow 70% confluency and
serum-deprived for 12 hours. GAS6 levels in culture super-
natants were measured using a quantitative immunoassay
ELISA kit (DuoSet ELISA Development Kit, R&D Systems).
Samples in triplicate were analyzed at 450 nm with an ELISA
reader (Model 550 microplate reader, Bio-Rad).
Matrigel invasion
In vitro invasiveness through Matrigel was assayed using
transwell cell culture chambers according to described pro-
cedures (4). Cells (1105 cells/well) were added to the upper
chamber of a prehydrated polycarbonate membrane filter of 8
mmol/L pore size (Costar, Cambridge) coated with Matrigel
(Collaborative Research) and then incubated at 37C in a
humidified incubator in 5% CO2 and 95% air for 24 hours.
Migrating cells on the reverse side of the filter were stained
with 0.1% crystal violet in 20% methanol for 30 minutes, lysed
in 10% acetic acid, and analyzed at 570 nmol/L with an ELISA
reader (Model 550 microplate reader, Bio-Rad). The results
were expressed as percentage of migrating cells with respect
to the sh-CTR silenced ones.
Cell proliferation
S-phase entry was evaluated by 5-bromo-2-deoxyuridine
(BrdU) incorporation and indirect immunofluorescence
according to described procedures (4, 5). Cells were grown
on coverslips, serum starved for 12 hours, and treated with
recombinant human GAS6 (200ng/mL) for 24 hours. More-
over, cells were silenced with siRNA (Dharmacon) for 24
hours, serum-deprived for 12 hours, and then treated with
recombinant human GAS6 (200ng/mL) for 24 hours. BrdU was
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added at a concentration of 10 mmol/L and BrdU-positive cells
were revealed with Texas-Red–conjugated secondary antibo-
dies (Jackson Immuno Research Laboratories).
For growth curves, cells were plated at a density of 0.5 105
in low serum conditions (2.5%) and counted at the indicated
time-points.
Flow cytometric analysis (FACS)
Cells were transfected with control siRNA (siCTR) or AXL-
targeting siRNAs (siAXL) and 48 hours later detached from
culture dishes with a solution of 0.5 mmol/L EDTA. After
saturation with 1 mg of human IgG/105 cells, cells were incu-
bated for 20 minutes on ice with antibodies against AXL
extracellular domain (R&D Systems) or isotype control anti-
body. Unreacted antibody was removed and cells were incu-
bated with phycoerytrin-labeled secondary antibodies (R&D
Systems). Cells resuspended in PBS were analyzed on a FACS-
Calibur cytofluorimeter using the CellQuest software (Becton
Dickinson). Analyses were done in triplicate. In each analysis, a
total of 104 events were calculated.
TUNEL assay
For TUNEL, an equal number (5  103) of cells was seeded
onto single-well Costar glass slides; after 24 hours of silencing,
cells were serum-deprived for 12 hours and treated with GAS6
(200 ng/mL) for 24 hours, and subjected to the TUNEL
reaction (Roche) as described elsewhere (4).
Xenografts in nude mice
Each group of 10 mice (4-week-old male BALB/c nu/nu
mice, Jackson Laboratories) was inoculated subcutaneously
into the right dorsal portion with 850-5C shCTR cells, 850-5C
shAXL Cl2, 850-5C shAXL CL4, or 850-5C shAXL CL6 (10106/
mouse). Tumor diameters were measured at regular intervals
with the caliper. Tumor volumes (V) were calculated with the
formula: V ¼ A  B2/2 (A ¼ axial diameter; B ¼ rotational
diameter). This study was conducted in accordance with
Italian regulations for experimentation on animals.
Statistical analysis
For comparisons between cell lines, we used the parametric
2-tailed t-test. To calculate the association between CXCR4
and AXL expression in PTCs, we used the 2-sided Fisher's
Exact Test, with the GraphPad Instat software, v.3.0b. Differ-
ences were statistically significant at P < 0.05.
Results
TYRO3 and AXL receptors are overexpressed and
activated in thyroid cancer cells
We carried out global gene expression profiling of human
TPC1 cells with or without SDF-1a. Among several genes,
TYRO3 and AXL were significantly upregulated. Quantitative
RT-PCR on selected genes and Western blot analysis on
TYRO3 and AXL confirmed these findings (Supplementary
Fig. S1A and B). Treatment of thyroid cancer cell lines with the
CXCR4 inhibitor AMD3100 inhibited SDF-1-mediated AXL
upregulation (data not shown), but not constitutive AXL
expression, indicating that other mechanisms are responsible
for this phenomenon. Thyroid cancer cell lines carry activated
oncogenes belonging to the RAS-BRAF-ERK, the p53 or the
PI3K/AKT pathway. TYRO3 and AXL protein levels were
undetectable in normal thyroid cells, whereas they were
significantly expressed in cancer cell lines (Fig. 1A). This
was also confirmed by RT-PCR experiments (Supplementary
Fig. S1C). AXL is activated in different cancer histotypes (21–
25). Thus, we evaluated its tyrosine-phosphorylation levels in
our cells by using both anti-phosphotyrosine and phospho-Tyr
779 (Y779) antibodies. Cancer cells displayed different degree
of AXL tyrosine-phosphorylation (Fig. 1A). TPC1 cells, derived
from a human PTC featuring a spontaneous RET/PTC1 rear-
rangement, showed the highest levels. Many thyroid cancer
cell lines (850-5C, NIM, and CAL62) expressed the AXL ligand
GAS6, but not TPC1 (Fig. 1B and Supplementary Fig. S1C). AXL
was also overexpressed in most of the oncogene-transfected
rat thyroid cells lines (PC Cl3) but not in PC E1A and PC BRAF
(Fig. 1C). Again, PC PTC cells show the highest level of AXL
phosphorylation (Fig. 1C). These data suggest that RET/PTC
may be involved in AXL activation through a ligand-indepen-
dent mechanism, whereas other genetic lesions induce a
ligand-dependent activation of the receptor. AXL, through a
C-terminal multidocking tyrosine (Y821), binds to several
substrates, such as p85 and GRB2. Tyrosine 779 was identified
as an additional p85-binding site (26). Although p85 activation
invariably results in the activation of the phosphatidylinosi-
tole 3-kinase (PI3-K)/Akt pathway, GRB2 can signal to both
the PI3-K/Akt and the extracellular regulatory kinase (ERK)
pathways (27). We analyzed the pattern of AXL-binding
proteins in TPC-1 and 850–5C cells by AXL immunoprecipita-
tion followed by immunoblotting with anti-phosphotyrosine
antibodies. p85, but not GRB2 (not shown), coprecipitated
with AXL (Fig. 1D). However, in p85 immunoprecipitates, we
could not detect AXL. This could be due to the interference of
p85 antibody with AXL/p85 interaction, or to the limiting
amount of endogenous proteins in our system. To distinguish
between these possibilities, we overexpressed AXL and p85 in
293T cells and showed the presence of AXL in p85 immuno-
precipitates and in GST-SH2 p85 pull-down assays (Supple-
mentary Fig. S2). By using TPC1 and 8505-C cell lysates, AXL
binding was detected in N-terminal p85 SH2- (Supplementary
Fig. S3), but not GRB2 SH2 (data not shown) pull-down
experiments. Consistently, the phosphorylation of AKT, but
not of ERK1/2, was observed upon GAS6 stimulation of
thyroid cancer cells (Supplementary Fig. S3). We also over-
expressed AXL and GRB2 in 293T cells. In this experiment, we
detected AXL-GRB2 coimmunoprecipitation, but GRB2 bind-
ing was not observed in pull-down assays (Supplementary
Fig. S2). Taken toghether, our data indicate that AXL can bind
to both p85 and GRB2. However, in thyroid cancer cells, it
preferentially binds to p85.
Human thyroid cancer specimens express Axl and Gas6
Twenty-seven thyroid carcinoma samples (9 PTCs, 10 FTCs,
and 8 PDC/ATCs) were analyzed by immunohistochemical
staining with an anti-human AXL antibody. Of all the samples
Avilla et al.
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Figure 1. A, analysis of TYRO3 and AXL protein levels and AXL
tyrosine-phosphorylation in a panel of human PTC and ATC cells
compared with the total AXL protein levels. Anti-tubulin
monoclonal antibody was used as a loading control. B, evaluation
of GAS6 levels in thyroid carcinoma cells by ELISA and Western
blot. C, analysis of AXL levels and tyrosine-phosphorylation by
AXL-immunoprecipitation followed by Western blot with anti-AXL
and anti-phosphotyrosine (PY) in a panel of parental (PC) and
transformed PC Cl3 rat thyroid cells. D, lysates from TPC1 and
850–5C cells were immunoprecipitated with anti-AXL and anti-p85
antibodies followed by Western blot with anti-phosphotyrosine,
anti-AXL, and anti-p85 antibodies.
Role of TAM Receptors in Human Thyroid Carcinoma
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analyzed, 73% (19/27) scored positive for AXL expression.
Normal thyroid was negative for AXL expression (Supplemen-
tary Table 1). AXL positivity was observed mainly in tumoral
cells (Fig. 2A). Most of the samples displayed membrane
positivity, but a small number of specimens showed cytosolic
staining into perinuclear vescicles probably representing the
Golgi apparatus, a typical pattern of overexpressed proteins.
Tumoral stroma and nontumoral adjacent tissues were nega-
tive, with the exception of red blood cells that were strongly
recognized by anti-AXL antibody as previously described (28).
We also assessed GAS6 expression by IHC in the same sample
set. Most of the analyzed specimens scored positive for GAS6
(Fig. 2A). GAS6 staining was cytosolic and mainly found in
carcinoma cells; some samples also displayed stromal posi-
tivity, suggesting that the ligand can also be provided by the
tumor microenvironment. As AXL was identified as a CXCR4-
SDF-1 target, we analyzed an independent set of PTCs (n¼ 30)
for both AXL and CXCR4 immunostaining (Fig. 2B). All
the CXCR4-positive samples (10/30) also coexpressed AXL
(10/10). AXL was expressed in 14 out of 30 samples. Thus,
CXCR4 expression positively correlated with AXL immunos-
taining (P < 0.005).
AXL/TYRO3-GAS6 blockade inhibits thyroid cancer cell
proliferation and survival
We analyzed the level of DNA synthesis by BrdU incorpora-
tion assays in serum-deprived TPC1 cells with and without
GAS6. Upon GAS6 stimulation, BrdU incorporation increased
from 10% to 20%. Consistently, a chimaeric protein (Dtk/FC)
that contains the extracellular domain of TYRO3 fused to the
FC portion of the IgG that sequesters GAS6, did not modify the
rate of BrdU-positive cells in basal conditions, but inhibited
the effects of GAS6 treatment (Supplementary Fig. S4A). Then,
we used RNA interference. AXL silencing was verified by
Western blot (Fig. 3A) and FACS analysis (Supplementary
Fig. S5). When AXL was silenced, we observed a reduction
of BrdU incorporation both in basal conditions (Fig. 3A) and in
the presence of GAS6: BrdU-positive cell rate dropped from
27% to 8%. GAS6 silencing did not modify TPC1 growth rate
(not shown), consistent with the observation that GAS6 is not
produced by these cells. To evaluate whether AXL blockade
influenced TPC1 survival, we treated these cells with a proa-
poptotic substance, diethylmaleate, for 12 hours, and carried
out TUNEL assays. In this condition, 48% of TUNEL-positive
cells were observed; GAS6 addition dramatically decreased
Figure 2. A, a representative
example of immunohisto-
chemistry on human thyroid
carcinomas (PTC, ATC) and
normal tissues (NT) with anti-AXL
and anti-GAS6 antibodies. B, the
same area of a human PTC
immunostained for AXL and
CXCR4 (PTC1). A negative sample
is also shown (PTC2).
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Figure 3. A, BrdU incorporation and TUNEL assay were evaluated in TPC1 cells after AXL and/or TYRO3 silencing in presence and in absence of
GAS6. Western blot analysis to verify AXL and TYRO3 silencing is shown. Three independent experiments were carried out in which at least 400 cells
were counted. B, BrdU incorporation and TUNEL assay of NIM cells treated or not with GAS6 and after AXL, GAS6, and TYRO3 silencing. Western blot
analysis to verify AXL, GAS6, and TYRO3 silencing is shown. C, BrdU incorporation and TUNEL assay of 850–5C cells with and without GAS6 and after AXL
silencing. Western blot analysis to verify AXL silencing is shown.
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this percentage. Dtk/FC decreased the percentage of
apoptotic cells only in the presence of exogenous GAS6
(Supplementary Fig. S4B). We also evaluated apoptosis in
AXL-silenced cells. After 12 hours serum deprivation, 10%
of apoptotic cells were observed. This percentage decreased to
5% when GAS6 was added. AXL silencing dramatically
increased the rate of apoptotic cells to 30%. Interestingly,
when GAS6 was added to AXL-silenced cells, the proapoptotic
effects of AXL silencing were significantly inhibited (Fig. 3A).
This effect could be due to incomplete AXL silencing. How-
ever, FACS analysis showed that RNAi almost completely
suppressed AXL expression (Supplementary Fig. S5). Alterna-
tively, TYRO3 can substitute AXL function. GAS6 silencing did
not modify the TPC1 cell apoptotic rate (not shown). As the
addition of GAS6 partially recovered the effects of AXL block-
ade in this cell line, we evaluated the effects of TYRO3
knockdown in TPC1 cells through RNA interference. As shown
in Figure 3A, TYRO3 silencing affected both BrdU incorpora-
tion and apoptosis. Silencing of both receptors increased the
effect of the single knockouts; finally, GAS6 treatment did not
modify the effect of the double knockouts. Similar experi-
ments were carried out by using NIM cells that express both
AXL and GAS6. Exogenous addition of this ligand did not
significantly modify BrdU incorporation and apoptosis rate of
NIM cells. Instead, the blockade of both endogenous AXL and
GAS6 by using RNAi or Dtk/FC inhibited NIM DNA synthesis,
and exogenous GAS6 addition reverted these effects. NIM
apoptosis induced by diethylmaleate or serum deprivation
was only slightly modified by GAS6 treatment. However, Dtk/
FC or AXL- or GAS6-silencing strongly enhanced NIM apop-
totic rate, and these effects were again reverted by exogenous
GAS6 (Fig. 3B and Supplementary Fig. S4). TYRO3 silencing
also affected NIM proliferation and survival, and TYRO3/AXL
silencing was as effective as GAS6; GAS6 treatment did not
modify the effects of TYRO3/AXL silencing. GAS6, TYRO3, and
AXL knockdown was verified by Western blot analysis
(Fig. 3B). We also used siRNA to verify whether AXL knock-
down could impair proliferation and survival of human 850–
5C and Cal62 ATC cells. GAS6 stimulated cell proliferation and
inhibited apoptosis both in 850–5C and in CAL62 cells and
AXL silencing had the opposite effect (Fig. 3C, Supplementary
Fig. S6).
Effects of stable silencing of AXL in 8505-C ATC cells
We selected 850–5C cells for their ability to induce tumor
formation in immunodeficient mice. We stably transfected
these cells with a pool of vectors expressing 5 different shRNAs
directed against AXL or expressing control nontargeting
shRNAs. We identified clones that expressed intermediate
(shAXL Cl 1 and 2) or low (shAXL Cl 3–6) AXL levels
(Fig. 4A). These results were confirmed by FACS analysis
(Fig. 4B). In 850–5C shAXL clones, the activation of the
PI3-K pathway (phosphorylation of Akt and of p70S6 Kinase),
was significantly reduced with respect to control or parental
cells (Fig. 4C). In contrast, the phosphorylation of ERK1/2 was
not affected by AXL silencing. We then verified whether AXL
knockdown could impair cell growth both in optimal (10%
FCS) or in low serum (2.5% FCS) conditions. AXL silencing
showed mild effects on cell proliferation in complete culture
medium (Supplementary Fig. S7), whereas it was significantly
more effective at low serum concentration (Fig. 5A). To assess
whether reduced cell growth was due to decreased DNA
synthesis or increased cell death, cells were serum starved
for 12 hours and the percentage of BrdU- and TUNEL-positive
cells was evaluated. All shAXL clones displayed a significant
reduction of BrdU incorporation and a significant increase in
Figure 4. A, screening of 850–5C
shAXL clones byWestern blot with
anti-AXL antibody. B, evaluation
of AXL levels in selected shCTR
and shAXL clones through FACS
analysis. C, evaluation of AXL-
mediated signaling pathways
shCTR and shAXL cloneswith anti-
phospho-AKT, -p70S6K, -ERK
antibodies. Equal protein loading
was verified with anti-AXL, -AKT,
-p70S6K, -ERK antibodies.
NT, normal tissue.
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apoptosis when compared with control clones, and these
effects were partially reverted by exogenous GAS6 (Fig. 5B).
Moreover, we asked whether AXL was necessary for ATC cell
invasiveness through Matrigel both in the absence and in the
presence of SDF-1a. shAXL clones showed a clear decrease of
invasive ability with respect to shCTR cells (Fig. 5C). SDF-1a
stimulated migration of cells displaying residual AXL expres-
sion, but was unable to do so in the AXL-negative clones,
suggesting that AXL is required for SDF-1 a-mediated cell
invasion of 850-5C cells. To rule out unspecific effects of the
AXL shRNAs, we decided to inhibit AXL through an alternative
strategy. We generated 850-5C cells expressing dominant-
negative AXL proteins, a truncated form of human AXL,
lacking the intracellular domain (AXL-EC), or a kinase-dead
mutant, carrying the substitution K558R (AXL KD). Phospho-
tyrosine blotting confirmed inhibition of AXL signaling
(Fig. 6A). AXL-EC and AXL KD inhibited AXL-mediated DNA
synthesis, cell survival, and cell migration (Fig. 6B, C, and D).
Figure 5. A, growth curves of 850–5C shCTR and shAXL clones done in 2.5% FBS. The average results of at least 3 independent determinations
were reported. B, BrdU incorporation was measured to evaluate S-phase entry of 850–5C shAXL and shCTR clones both in the absence and in the
presence of exogenous GAS6. TUNEL reaction was conducted on 850–5C shAXL and shCTR clones both in the presence and in the absence of exogenous
GAS6. C, Matrigel invasion assay on 850–5C shAXL clones. The results were expressed as percentage of 850–5C shAXL migrated cells with respect
to 850–5C shCTR.
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Axl silencing inhibits experimental tumor growth
Finally, we evaluated the role of AXL in tumor growth by
using xenografts of ATC cells into (nu/nu) immunodeficient
mice. We injected animals with parental, shCTR-transfected
(shCTR), and shAXL-expressing (Cl4 and Cl6) 850–5C cells, and
compared their growth rate. Parental cells formed tumors with
the same efficiency as shCTR-transfected cells did (not shown).
As shown in Fig. 7A, the tumorigenicity of 850–5C shAXL clones
was completely inhibited when compared with 850–5C shCTR
control cells. At 3 weeks, shCTR tumor median volume was 34
mm3, whereas shAXL was lesser than 10 mm3. At 4, 5, and 6
weeks, shCTR tumors continued to grow, reaching a median
volume of approximately 150mm3whereas shAXL did not, and
the few small tumors that appeared at 3 weeks eventually
regressed. At the end of the experiment, no shAXL tumors were
available. This precluded histological analysis. We then tested
the ability of 850–5C shAXL clones with intermediate levels of
AXL expression to induce tumor formation in nude mice. We
injectedmicewith shAXLCl2, that still retains some expression
of the receptor (Fig. 7B), and, as control, the shCTR clone. A few
small tumors appeared at 7 weeks postinjection in the shAXL
Cl2 group (Fig. 7B). At the end of the experiment, tumors were
excised and analyzed by IHC for proliferation, apoptosis, and
vascularization. A higher rate of apoptosis, but not of prolif-
eration of shAXL tumorswith respect to controlswas observed,
althoughdifferenceswere not statistically significant due to the
limited number of shAXL samples (Fig. 7C). Vessel density was
comparable between the 2 groups of tumors. However, in
shAXL tumors, vessels were not well formed and their median
diameter was smaller than that of shCTR clones (P < 0.05).
These data indicate that AXL is required for 850–5C xenograft
growth in nude mice.
Discussion
In the search for SDF-1 transcriptional targets in thyroid
cancer, we identified 2 tyrosine-kinase receptors, TYRO3 and
AXL. AXL overexpression has been reported in a variety of
human cancers (21, 24, 28–36), and it is associated with
negative prognosis (14, 24, 25, 37–39). AXL expression confers
resistance to different antineoplastic agents (40–42), can
induce angiogenesis (14, 43), cancer cell migration and inva-
sion (37, 44–46).
We found that TYRO3 and AXL are transcriptionally regu-
lated by CXCR4-SDF-1. However, these receptors were con-
stitutively expressed in human thyroid cancer cells, but not in
normal thyroid. AXL expression was also detected in thyroid
cancer samples, but not in normal thyroid tissues, and the
presence of AXL positively correlated with CXCR4 expression.
Rat thyroid cancer cells (PC) expressing different activated
oncogenes also expressed AXL, with the exception of PC BRAF
and PC E1A. These data indicate that multiple mechanisms,
besides CXCR4 activation, can contribute to increase AXL
levels in thyroid cancer. The activation of components of the
RAS/MAPK pathway is frequently found in human PTC.
However PC PTC, but not PC BRAF cells, express AXL, despite
both display activated MAPKs. This suggests that the RAS/
MAPK pathway is not sufficient to activate AXL expression.
Cancer-associated transcription factors, promoter hypo-
methylation or gene amplification may result in AXL over-
expression. Interestingly, AXL is strongly induced by
epithelial-to-mesenchimal transition (37) or by a v-FLIP-
NFKB pathway (47). Preliminary data obtained by us failed
to show gene mutation or amplification in thyroid cancer cell
lines (Krishnamoorthy, unpublished observations). However,
other possible mechanisms of AXL expression in thyroid
cancer need to be investigated. AXL was constitutively phos-
phorylated in most of the human thyroid cancer cells. This
was due to the presence of the ligand GAS6; the only exception
was the TPC1 cell line, in which AXL was highly phosphory-
lated despite ligand absence. In this case, some other mechan-
isms, such as Ret-mediated ligand-independent activation of
AXL, may keep the receptor in a constitutively active status.
Consistently, a cross-talk between EGFR family members and
AXL has been suggested (38, 42). The inhibition of TYRO3,
AXL, or GAS6 reduced cell proliferation and increased apop-
totic rate. AXL silencing in 850–5C ATC cells dramatically
reduced thyroid cancer cell invasive ability, and SDF-1 could
not rescue this capability, indicating that AXL is required for
SDF-1-mediated chemotactic activity. These results are in
accord with previous data indicating that AXL is involved
in cell migration and invasion (37, 44). AXL is also involved in
angiogenesis (14, 43). Accordingly, in our xenograft system,
AXL silencing strongly inhibited 850–5C tumor formation, and
this effect was mainly due to impaired vessel formation in
xenografts. We also observed increased apoptosis in 850–5C
shAXL induced tumors with respect to the normal counter-
part. However, differences in the apoptotic rate were not
statistically significant. Thus, in our thyroid cancer model,
AXL seems to be required for the initial steps of tumor
formation. Other studies have shown that AXL is required
for breast cancer cell xenograft growth in nude mice, but it
was not required for orthotopic breast tumor formation.
However, it was necessary for invasion and metastasis (37).
Differences in AXL requirement between subcutaneously- or
orthotopically-injected breast tumors suggested a specific
function for this receptor to drive growth and colonization
in an unfavorable environment (48, 49). Whether orthotopic
thyroid tumor formation in syngeneic animals requires AXL is
currently unknown. In breast cancer, AXL expression has been
associated with the presence of metastasis and it represents a
negative prognostic factor (37). We have analyzed a limited
number (n ¼ 27) of thyroid cancer samples, ranging from the
well-differentiated PTC and FTC to the completely undiffer-
entiated ATC, and we found that AXL expression was equally
distributed in all 3 histotypes. This analysis, although done on
a small number of patients, indicates that AXL expression may
be an initial event of thyroid transformation, but it is some-
times retained during thyroid cancer progression. TYRO3,
often coexpressed with AXL in thyroid cancer cells, is also
important for thyroid cancer cell viability. However, tumor-
igenesis in nude mice is strictly dependent on AXL.
In conclusion, our data strongly suggest that AXL/TYRO3-
GAS6 axis can be considered as a novel potential target of
thyroid anticancer therapy. Several compounds have been
identified that block AXL signaling by acting at different levels
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Figure 6. A, schematic representation of wt and mutant AXL. AXL-EC includes Aa 1 to 508, whereas AXL KD contains the substitution K558R. FLAG and
myc-his epitopes are indicated. Exogenous AXL KD and AXL EC expression in different clones was verified by Western blot analysis with anti-myc
and anti-FLAG antibodies, respectively. 850–5C AXL KD cl 1 and AXL EC MP1 were also analyzed for AXL phosphorylation through anti-phospho-AXL
immunoblot. B, Matrigel invasion assay on control (pcDNA3.1), AXL KD- and AXL EC- 850–5C cells. The results were expressed as the percentage of
migrating cells with respect to controls. C, BrdU incorporation and TUNEL assays were carried out to evaluate S-phase entry and apoptosis of 850–5C (NT),
empty vector-transfected (pcDNA3.1), and AXL mutant clones. The percentage of apoptotic cells was measured by TUNEL assay in 850–5C (NT), empty
vector-transfected (pcDNA3.1), and AXL mutant clones. NT, normal tissue.
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Figure 7. A, three groups of 10 nude mice injected with 850–5C shCTR or 850–5C shAXL CL4 or CL6 cells were evaluated for tumor growth. All P values
were 2-sided, and differences were statistically significant at P < 0.05. B, 2 groups of 10 nude mice injected with 850–5C shCTR cells or 850–5C shAXL
Cl2 that expressed intermediate levels of AXL were evaluated for tumor growth. Mice inoculated with shAXL Cl2 formed tumors after 7 weeks, but
their size was smaller than that of shCTR tumors. C, IHC on excised shAXL Cl2 and shCTR tumors for ki67, CD31, and Tunel. Mean vessel diameter
was significantly lower in shAXL than in control clones; *P < 0.02.
Avilla et al.
Cancer Res; 71(5) March 1, 2011 Cancer Research1802
 American Association for Cancer Research Copyright © 2011 
 on November 15, 2012cancerres.aacrjournals.orgDownloaded from 
Published OnlineFirst February 22, 2011; DOI:10.1158/0008-5472.CAN-10-2186
(43, 44, 49, 50). Our data indicate that these compounds should
be exploited to treat thyroid cancer.
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